<!DOCTYPE html>
<!-- saved from url=(0043)https://bestpractice.bmj.com/topics/en-gb/8 -->
<html lang="en-gb" class="">
   <head>
      <meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
      <title>Acute exacerbation of chronic obstructive pulmonary disease - Symptoms, diagnosis and treatment | BMJ Best Practice</title>
      <meta http-equiv="X-UA-Compatible" content="IE=edge,chrome=1">
      <meta name="viewport" content="width=device-width, initial-scale=1, shrink-to-fit=no">
      <meta name="apple-itunes-app" content="app-id=1105379489">
      <meta name="description" content="Typically presents with an increased level of dyspnoea, worsening of chronic cough, and/or an increase in the volume and/or purulence of the sputum produced. May represent the first presentation of COPD, usually associated with a history of tobacco exposure. Treatment includes bronchodilators, sy...">
      <meta name="author" content="Carolyn L. Rochester">
      <meta name="author" content="Richard A. Martinello">
      <!-- Optimize Page Hiding Snippet --> 
      <!-- <style>.async-hide
         { opacity: 0 !important}
      </style>
      <script async="" src="../js/adrum-ext.0086dbec5e8a6e717bf36d3a06b62042.js"></script><script src="../js/414393182248444.js" async=""></script><script async="" src="../js/fbevents.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/get-loader.js"></script><script type="text/javascript" async="" src="../js/insight.min.js"></script><script type="text/javascript" async="" src="../js/js"></script><script type="text/javascript" async="" src="../js/uwt.js"></script><script type="text/javascript" async="" src="../js/4896.js"></script><script type="text/javascript" async="" src="../js/analytics.js"></script><script async="" src="../js/gtm.js"></script><script>(function(a,s,y,n,c,h,i,d,e){s.className+=' '+y;h.start=1*new Date; h.end=i=function()
         {s.className=s.className.replace(RegExp(' ?'+y),'')}
         ; (a[n]=a[n]||[]).hide=h;setTimeout(function()
         
         {i();h.end=null}
         ,c);h.timeout=c;})(window,document.documentElement,'async-hide','dataLayer',3000,
         
         {'GTM-K3TZ3JV':true}
         );
      </script> -->
      <!-- end Optimize Page Hiding Snippet -->
      <!-- Google Tag Manager -->
      <!-- <script>
         /*<![CDATA[*/
         
          
         window.dataLayer = window.dataLayer || [];
         window.dataLayer.push({
                    'icsId': "id6370964",
                    'pi_icsId': "id82087",
                    'pi_icsName': "BMJ Group (Online access from BMA House)",
                    'access_rights': true,
                    'ics_groupings': [{"name":"Country Grouping"},{"name":"bmj.com:registrant"},{"name":"bp-institutional-users:registrant"}],
                    'ics_countryName': "GB and ROW",
                    'siteLanguage': "en-gb",
                    'contentLanguage': "en-gb"
                 });
         		  
         /*]]>*/
            
      </script> -->
      <script>
         (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
         new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
         j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
         'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
         })(window,document,'script','dataLayer', 'GTM-K3TZ3JV');
      </script>
      <!-- End Google Tag Manager -->
      <!-- /* if user in China */ -->
      <link rel="stylesheet" type="text/css" media="screen" href="../css/material.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/styles.css">
      <link rel="stylesheet" type="text/css" media="screen" href="../css/external.css">
      <link rel="shortcut icon" href="https://resources.bmj.com/repository/images/favicon.ico">
      <link rel="canonical" href="https://bestpractice.bmj.com/topics/en-gb/8">
      <link rel="alternate" hreflang="uk-ua" href="https://bestpractice.bmj.com/topics/uk-ua/8">
      <link rel="alternate" hreflang="en-ie" href="https://bestpractice.bmj.com/topics/en-gb/8">
      <link rel="alternate" hreflang="az-az" href="https://bestpractice.bmj.com/topics/az-az/8">
      <link rel="alternate" hreflang="ru" href="https://bestpractice.bmj.com/topics/ru-ru/8">
      <link rel="alternate" hreflang="en-us" href="https://bestpractice.bmj.com/topics/en-us/8">
      <link rel="alternate" hreflang="pt" href="https://bestpractice.bmj.com/topics/pt-br/8">
      <link rel="alternate" hreflang="ka-ge" href="https://bestpractice.bmj.com/topics/ka-ge/8">
      <link rel="alternate" hreflang="pt-br" href="https://bestpractice.bmj.com/topics/pt-br/8">
      <link rel="alternate" hreflang="es-es" href="https://bestpractice.bmj.com/topics/es-es/8">
      <link rel="alternate" hreflang="en" href="https://bestpractice.bmj.com/topics/en-gb/8">
      <link rel="alternate" hreflang="zh-cn" href="https://bestpractice.bmj.com/topics/zh-cn/8">
      <link rel="alternate" hreflang="es" href="https://bestpractice.bmj.com/topics/es-es/8">
      <link rel="alternate" hreflang="zh" href="https://bestpractice.bmj.com/topics/zh-cn/8">
      <link rel="alternate" hreflang="x-default" href="https://bestpractice.bmj.com/topics/en-gb/8">
      <link rel="alternate" hreflang="ru-ru" href="https://bestpractice.bmj.com/topics/ru-ru/8">
      <link rel="alternate" hreflang="vi" href="https://bestpractice.bmj.com/topics/vi-vn/8">
      <link rel="alternate" hreflang="uk" href="https://bestpractice.bmj.com/topics/uk-ua/8">
      <link rel="alternate" hreflang="ka" href="https://bestpractice.bmj.com/topics/ka-ge/8">
      <link rel="alternate" hreflang="az" href="https://bestpractice.bmj.com/topics/az-az/8">
      <link rel="alternate" hreflang="vi-vn" href="https://bestpractice.bmj.com/topics/vi-vn/8">
      <link rel="alternate" hreflang="en-gb" href="https://bestpractice.bmj.com/topics/en-gb/8">
      <!--[if lte IE 9]>
      <link rel="stylesheet" type="text/css" media="screen" href="/gzip_1791a8687c5480ce19e791d0825e7a6b/css/lte-ie-9.css" >
      <![endif]-->
      <script>
         /*<![CDATA[*/
           var appdynamics_app_key="AD-AAB-AAF-RGR";
         /*]]>*/
           	window["adrum-app-key"] = appdynamics_app_key;
           	window['adrum-start-time'] = new Date().getTime();
           
      </script>
      <script type="text/javascript" src="../js/appdynamics.js"></script>
      <script type="application/ld+json">
         [
         
         { "@context": "http://schema.org", "@type": "MedicalCondition" }
         ,{
         "isAccessibleForFree": "False",
         "hasPart":
         
         { "@type": "WebPageElement", "isAccessibleForFree": "False", "cssSelector" : ".gpw" }
         }]
      </script>
      <meta name="msvalidate.01" content="76FD53F39FDFB050A93D7925608BA016">
      <style type="text/css">._6772342E312E39_src-lib-Adapter-styles__centerStyle--2U8wI, ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M, ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio, ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         top: 50%;
         position: absolute;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         box-sizing: border-box;
         padding: 0;
         border-radius: 3px;
         position: fixed;
         display: block;
         visibility: visible;
         bottom: 0;
         background-color: #f3f3f3;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, -webkit-transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.1s 0s ease-in-out, -webkit-transform 0.1s 0s ease-in-out;
         z-index: 99999;
         box-shadow: 0px 0px 5px 1px rgba(0, 0, 0, 0.18);
         overflow: hidden;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__right--2Mb43 {
         right: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dragging--2uZno {
         transition: opacity 0.1s 0s linear;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__closed--eHbpJ {
         visibility: hidden;
         opacity: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__loading--1ewAG {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         position: relative;
         height: 35px;
         line-height: 35px;
         min-width: 165px;
         text-align: center;
         cursor: move;
         z-index: 11;
         overflow: hidden;
         font-family: Helvetica;
         font-weight: normal;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         cursor: ew-resize;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         left: 50%;
         height: 16px;
         width: 100px;
         margin-top: -8px;
         margin-left: -50px;
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 20px;
         height: 14px;
         width: 14px;
         border-radius: 8px;
         margin-top: -7px;
         display: none;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__dropdownPresence--18mrh {
         display: none;
         position: absolute;
         width: 100%;
         height: 100vh;
         }
         ._6772342E312E39_src-lib-Adapter-styles__showDropdown--242EQ {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj {
         padding: 10px 15px;
         display: block;
         cursor: pointer;
         text-decoration: none;
         text-align: left;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceItem--3ODPj:hover {
         background-color: #f5f5f5;
         }
         ._6772342E312E39_src-lib-Adapter-styles__selected--1z5-3 {
         color: #0684bd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM {
         position: relative;
         width: 160px;
         min-width: 165px;
         left: 5px;
         padding: 0;
         min-height: 30px;
         box-sizing: border-box;
         box-shadow: 0 0 4px 0 rgba(0, 0, 0, 0.2);
         background-color: #ffffff;
         border-style: solid;
         border-width: 0;
         border-top-width: 1px;
         border-bottom-width: 0px;
         border-color: #eeeeee;
         border-radius: 4px;
         font-family: "Helvetica Neue", Helvetica, Arial, sans-serif;
         font-size: 14px;
         color: #2F2F2F;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__horizontal--1DydQ {
         display: inline-flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__clickable--G0zEI {
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__line--3f7OM ._6772342E312E39_src-lib-Adapter-styles__noborder--1ysDv {
         border: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         left: 10px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Offline--3PnxB {
         display: block;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Busy--IDedL {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__Available--2GLYE {
         display: block;
         background-color: #32ae31;
         }
         ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: none;
         position: absolute;
         width: 8px;
         height: 2px;
         border-radius: 1.5px;
         background-color: #ffffff;
         -webkit-transform-origin: 50% 50%;
         transform-origin: 50% 50%;
         -webkit-transform: translate(3px, 6px);
         transform: translate(3px, 6px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo {
         display: block;
         background: #f95b5c;
         }
         ._6772342E312E39_src-lib-Adapter-styles__DoNotAcceptAnyCalls--1WuKo ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         display: block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__statusIcon--2SoFd {
         display: inline-block;
         position: relative;
         margin-right: 5px;
         top: 2px;
         left: 0;
         margin-top: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw {
         box-sizing: border-box;
         height: 20px;
         width: 20px;
         margin-top: -12px;
         border-radius: 3px;
         cursor: pointer;
         border-style: solid;
         border-width: 1px;
         border-color: transparent;
         }
         ._6772342E312E39_src-lib-Adapter-styles__button--3aSCw:hover {
         border-color: #cccccc;
         }
         ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 40px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__toggle--2EHo_ {
         right: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         position: absolute;
         box-sizing: border-box;
         left: 3px;
         bottom: 7px;
         width: 12px;
         height: 2px;
         border: 1px solid #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__minimizeIcon--NnVNt {
         height: 12px;
         bottom: 3px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimizeIconBar--2WYhn {
         width: 100%;
         height: 1px;
         background-color: #888888;
         }
         ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__close--1qEO1 {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR {
         position: relative;
         overflow: hidden;
         margin: 2px;
         width: 14px;
         height: 14px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child, ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         position: absolute;
         height: 2px;
         width: 100%;
         top: 6px;
         left: 0;
         background: #888888;
         border-radius: 1px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :first-child {
         -webkit-transform: rotate(45deg);
         transform: rotate(45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__closeIcon--gYGuR :last-child {
         -webkit-transform: rotate(-45deg);
         transform: rotate(-45deg);
         }
         ._6772342E312E39_src-lib-Adapter-styles__contentFrame--Z6dLx {
         display: block;
         border: none;
         width: 0;
         height: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.1s 0s ease-in-out, height 0.1s 0s ease-in-out;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__glow--1aZft {
         0% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         40%, 50% {
         box-shadow: inset 0 0 7px 0px #0684bd;
         }
         100% {
         box-shadow: inset 0 0 7px -10px #0684bd;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__ringing--2c7d0 {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__glow--1aZft;
         -webkit-animation-duration: 2s;
         animation-duration: 2s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: infinite;
         animation-iteration-count: infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         0% {
         display: none;
         top: -50%;
         }
         100% {
         display: inline-block;
         top: 50%;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         @keyframes _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         0% {
         display: inline-block;
         top: 50%;
         }
         100% {
         top: 150%;
         display: none;
         }
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveIn--339sz {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveIn--339sz;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa {
         -webkit-animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         animation-name: _6772342E312E39_src-lib-Adapter-styles__moveOut--FFYLa;
         -webkit-animation-duration: 1s;
         animation-duration: 1s;
         -webkit-animation-timing-function: ease-in-out;
         animation-timing-function: ease-in-out;
         -webkit-animation-iteration-count: 1;
         animation-iteration-count: 1;
         -webkit-animation-fill-mode: forwards;
         animation-fill-mode: forwards;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 33px;
         margin-left: -60px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__duration--3PGiS._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV {
         position: absolute;
         top: -50%;
         left: 50%;
         height: 16px;
         line-height: 16px;
         margin-top: -8px;
         color: #666666;
         font-size: 12px;
         white-space: nowrap;
         width: 100px;
         margin-left: -100px;
         text-overflow: ellipsis;
         overflow: hidden;
         text-align: center;
         }
         ._6772342E312E39_src-lib-Adapter-styles__ringingCalls--2-nNV._6772342E312E39_src-lib-Adapter-styles__center--3fFya, ._6772342E312E39_src-lib-Adapter-styles__onHoldCalls--3TETV._6772342E312E39_src-lib-Adapter-styles__center--3fFya {
         margin-left: -50px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #5FB95C;
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX:hover {
         color: #5FB95C;
         }
         ._6772342E312E39_src-lib-Adapter-styles__currentCallBtn--3k6uX._6772342E312E39_src-lib-Adapter-styles__left--1ROKY {
         margin-left: -80px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL {
         position: absolute;
         top: -50%;
         left: 50%;
         padding: 0 5px;
         height: 18px;
         line-height: 18px;
         border-radius: 10.5px;
         font-size: 11px;
         margin-top: -10px;
         margin-left: -13px;
         overflow: hidden;
         white-space: nowrap;
         min-width: 66px;
         max-width: 110px;
         cursor: pointer;
         border: solid 1px #FF8800;
         color: #FF8800;
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL:hover {
         color: #FF8800;
         }
         ._6772342E312E39_src-lib-Adapter-styles__viewCallsBtn--1W1UL._6772342E312E39_src-lib-Adapter-styles__visible--VAtK5 {
         display: inline-block;
         margin-top: -10px;
         top: 50%;
         }
         ._6772342E312E39_src-lib-Adapter-styles__detectNew--2RyZg {
         background: url("https://rc-hack-new.detect");
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1 {
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out;
         transition: visibility 0.2s 0s linear, opacity 0.2s 0s linear, transform 0.2s 0s ease-in-out, width 0.2s ease-in-out, -webkit-transform 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         top: initial !important;
         width: 300px;
         border-top-right-radius: 0;
         border-bottom-right-radius: 0;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg {
         width: 60px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__root--SzEr1._6772342E312E39_src-lib-Adapter-styles__dock---5JfC._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         width: 35px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         opacity: 0 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconTrans--2LRAZ ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M {
         opacity: 1 !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__expandable--1dLZX {
         width: 140px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg._6772342E312E39_src-lib-Adapter-styles__header--2NQqI {
         line-height: initial;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presence--30Tio {
         width: 12px;
         height: 12px;
         margin-top: -6px;
         z-index: 2;
         transition: .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__presenceBar--1TIQL {
         -webkit-transform: translate(2px, 5px);
         transform: translate(2px, 5px);
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__logo--28R_M._6772342E312E39_src-lib-Adapter-styles__dock---5JfC {
         opacity: 0;
         transition: opacity .2s;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv {
         z-index: 2147483648;
         top: 7px;
         position: absolute;
         left: 30px;
         height: 22px;
         width: 22px;
         display: block;
         cursor: pointer;
         opacity: 1;
         transition: .3s;
         display: flex;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv ._6772342E312E39_src-lib-Adapter-styles__icon--2I9x4 {
         width: 22px;
         height: 22px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-Adapter-styles__iconContainer--2u4Jv._6772342E312E39_src-lib-Adapter-styles__noPresence--gCXYu {
         left: 7px !important;
         }
         ._6772342E312E39_src-lib-Adapter-styles__frameContainer--Wtvcz {
         overflow: hidden;
         transition: width 0.2s 0s ease-in-out, height 0.2s 0s ease-in-out;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         right: 16px;
         }
         ._6772342E312E39_src-lib-Adapter-styles__minimized--2g_Jg ._6772342E312E39_src-lib-Adapter-styles__popOut--2sH2z {
         display: none;
         }
         ._6772342E312E39_src-lib-Adapter-styles__popOutIcon--oudoy img {
         position: absolute;
         top: 3px;
         left: 1px;
         width: 14px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         display: none;
         height: 30px;
         left: 0;
         position: fixed;
         top: 0;
         -webkit-transform: opacity 0.1s 0s linear;
         transform: opacity 0.1s 0s linear;
         z-index: 999999999;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         -webkit-user-select: none;
         -moz-user-select: none;
         -ms-user-select: none;
         user-select: none;
         user-drag: none;
         background-color: rgba(255, 255, 255, 0.95);
         box-sizing: border-box;
         border: 1px solid #cfcfcf;
         border-radius: 4px;
         font-size: 0px;
         height: 30px;
         white-space: nowrap;
         margin: 0 0 0 5px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 img {
         vertical-align: baseline !important;
         display: inline-block !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05 {
         margin: 0 5px 0 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #cfcfcf;
         top: calc(50% - 5px);
         left: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         position: absolute;
         border-top: 5px solid transparent;
         border-bottom: 5px solid transparent;
         border-right: 5px solid #FF8800;
         top: calc(50% - 5px);
         left: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr {
         border-right: none;
         border-left: 5px solid #cfcfcf;
         left: initial;
         right: 0;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__left--2MAWB ._6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO {
         border-right: none;
         border-left: 5px solid #fff;
         left: initial;
         right: 1px;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU {
         height: 30px;
         width: 30px;
         margin: -1px 0 0 -1px;
         vertical-align: baseline;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: none;
         position: relative;
         vertical-align: top;
         cursor: pointer;
         font-size: 18px;
         height: 28px;
         width: 28px;
         line-height: 28px;
         text-align: center;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI:hover, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 {
         display: none;
         width: 1px;
         height: 19px;
         margin: 5px 0;
         background: #cdcdcd;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7:hover {
         opacity: 0.6;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7._6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v {
         display: inline-block;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__hack--5AVJK {
         background: url("https://rc-hack-c2d.detect");
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg {
         position: absolute;
         top: 50%;
         left: 50%;
         -webkit-transform: translateX(-50%) translateY(-50%);
         transform: translateX(-50%) translateY(-50%);
         overflow: visible !important;
         }
         ._6772342E312E39_src-lib-ExtensionContentRunner-styles__btn--2BjPK svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI svg > path, ._6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc svg > path {
         fill: #0684bd;
         stroke: #0684bd;
         }
      </style>
      <style type="text/css">add-meeting-button {
         line-height: 36px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__root--3CtVK {
         margin-left: 8px;
         position: relative;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q {
         min-width: 94px;
         white-space: nowrap;
         height: 26px;
         line-height: 26px;
         padding: 0;
         font-size: 11px;
         font-weight: 500;
         text-align: center;
         color: #0684bd;
         background: #fff;
         border-radius: 20px;
         border: 1px solid #9bcee5;
         font-family: Roboto, Helvetica, Arial, sans-serif;
         font-weight: 400;
         outline: none;
         cursor: pointer;
         transition: .3s;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q:hover {
         color: #fff;
         background-color: #9bcee5;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1 {
         color: #fff;
         background-color: #c7c7c7;
         border: 1px solid #c7c7c7;
         cursor: default;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__button--sCE0Q._6772342E312E39_src-lib-MeetingHelper-Page-styles__disabled--12Fo1:hover {
         cursor: default;
         background-color: #c7c7c7;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__or--Hsdgj {
         float: left;
         margin-left: 10px;
         font-size: 12px;
         color: #0684bd;
         display: none;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__icon--r7sAL {
         left: 5px;
         top: 4px;
         width: 18px;
         height: 18px;
         position: absolute;
         background: #fff;
         border-radius: 100%;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__text--1nLnV {
         width: 100%;
         margin-left: 25px;
         padding-right: 6px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-Page-styles__meetingContainer--24va2 {
         display: flex;
         flex-grow: 100;
         align-items: center;
         }
      </style>
      <style type="text/css">#rc-meeting-popup-window {
         width: 100%;
         height: 100%;
         background-color: rgba(0, 0, 0, 0.3);
         display: flex;
         justify-content: center;
         align-items: center;
         line-height: normal;
         text-align: left;
         position: fixed;
         z-index: 2147483647;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__container--2qd2O {
         width: 470px;
         height: auto;
         display: flex;
         flex-direction: column;
         align-items: stretch;
         overflow: hidden;
         box-shadow: 0 24px 38px 3px rgba(0, 0, 0, 0.14), 0 9px 46px 8px rgba(0, 0, 0, 0.12), 0 11px 15px -7px rgba(0, 0, 0, 0.2);
         border-radius: 2px;
         position: relative;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA {
         position: relative;
         width: 100%;
         height: 30px;
         line-height: 30px;
         font-size: 12px;
         box-sizing: border-box;
         background: #ffffff;
         padding-left: 15px;
         padding-top: 10px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__recurringMeetingPrompt--3U97a {
         margin: 5px 22px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X {
         position: absolute;
         top: 13px;
         right: 15px;
         color: rgba(0, 0, 0, 0.54);
         fill: rgba(0, 0, 0, 0.54);
         width: 20px;
         height: 20px;
         cursor: pointer;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__closeBtn--1JJ_X svg {
         width: 20px;
         height: 20px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__wrapper--3DttD {
         background-color: #ffffff;
         width: 100%;
         padding: 10px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settings--15yhX {
         border-radius: 3px;
         box-sizing: border-box;
         padding: 0 8px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryLabel--2n8iQ {
         margin: 10px 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__categoryWrapper--2LA96 {
         border-radius: 3px;
         background-color: #F9F9F9;
         border: 1px solid #E2E2E2;
         padding: 9px 16px;
         box-sizing: border-box;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__settingLabel--ybCle {
         display: inline-block;
         width: 80px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF {
         line-height: 20px;
         margin: 7px 0;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF * {
         vertical-align: middle;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__video--1oJss {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__audio--2dr2m {
         margin-left: 15px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__line--359ZF input:first-of-type {
         margin-left: 0;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__controls--1GgrW {
         margin: 10px 0 10px 10px;
         height: 30px;
         line-height: 30px;
         display: flex;
         align-items: center;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__schedule--3SMpg {
         background: #4285f4;
         color: #fff;
         transition: box-shadow 0.28s cubic-bezier(0.4, 0, 0.2, 1);
         box-shadow: 0 2px 2px 0 rgba(0, 0, 0, 0.14), 0 3px 1px -2px rgba(0, 0, 0, 0.12), 0 1px 5px 0 rgba(0, 0, 0, 0.2);
         border: 0;
         border-radius: 3px;
         cursor: pointer;
         display: inline-block;
         font-weight: 500;
         outline: none;
         overflow: hidden;
         text-align: center;
         z-index: 0;
         font-size: 12px;
         line-height: 30px;
         height: 32px;
         min-width: 88px;
         position: absolute;
         right: 18px;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__header--axhLA span {
         font-size: 16px;
         display: inline-block;
         }
         ._6772342E312E39_src-lib-MeetingHelper-PopupWindow-styles__password--3Ij_s {
         display: none;
         margin-left: 10px;
         }
      </style>
      <style type="text/css">._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__spinner--18fX2 {
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP 1.4s linear infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__rotator--5WHNP {
         0% {
         -webkit-transform: rotate(0deg);
         transform: rotate(0deg);
         }
         100% {
         -webkit-transform: rotate(270deg);
         transform: rotate(270deg);
         }
         }
         ._6772342E312E39_src-lib-MeetingHelper-Spinner-styles__path--2xqMm {
         stroke-dasharray: 187;
         stroke-dashoffset: 0;
         -webkit-transform-origin: center;
         transform-origin: center;
         -webkit-animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         animation: _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k 1.4s ease-in-out infinite, _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q 5.6s ease-in-out infinite;
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__colors--26t3q {
         0% {
         stroke: #4285F4;
         }
         25% {
         stroke: #DE3E35;
         }
         50% {
         stroke: #F7C223;
         }
         75% {
         stroke: #1B9A59;
         }
         100% {
         stroke: #4285F4;
         }
         }
         @-webkit-keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
         @keyframes _6772342E312E39_src-lib-MeetingHelper-Spinner-styles__dash--2lb9k {
         0% {
         stroke-dashoffset: 187;
         }
         50% {
         stroke-dashoffset: 46.75;
         -webkit-transform: rotate(135deg);
         transform: rotate(135deg);
         }
         100% {
         stroke-dashoffset: 187;
         -webkit-transform: rotate(450deg);
         transform: rotate(450deg);
         }
         }
      </style>
      <style></style>
   </head>
   <body>
     
    <div role="dialog" aria-live="polite" aria-label="cookieconsent" aria-describedby="cookieconsent:desc" class="cc-window cc-banner cc-type-info cc-theme-classic cc-bottom cc-color-override--38786966 cc-invisible" style="display: none;">
         <!--googleoff: all--><span id="cookieconsent:desc" class="cc-message">We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our 
         <a aria-label="learn more about cookies" role="button" tabindex="0" class="cc-link" href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">cookies policy</a></span>
         <div class="cc-compliance"><a aria-label="dismiss cookie message" role="button" tabindex="0" class="cc-btn cc-dismiss">OK!</a></div>
         <!--googleon: all-->
     </div>
      <!-- Google Tag Manager (noscript) -->
      <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-K3TZ3JV" height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
      <!-- End Google Tag Manager (noscript) -->
      <!-- /* if user in China */ -->
      <header id="header" role="banner">
         <a class="sr-only" href="https://bestpractice.bmj.com/topics/en-gb/8#sr-content">Skip to main content</a>
         <div class="bg-info text-white">
         </div>
         <nav id="globalNav" class="logo-img-mob navbar navbar-toggleable-md">
            <div class="container">
               <a href="https://bestpractice.bmj.com/" class="mobLogo"><span class="remove"><abbr>BMJ</abbr> Best Practice</span></a>
               <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarNav" aria-controls="navbarNav" aria-expanded="false" aria-label="Toggle navigation">
               <span class="material-icons"></span>
               </button>
               <div id="navbarNav" class="collapse navbar-collapse">
                  <ul id="globalNav-ul" class="navbar-nav" role="menubar">
                     <li id="globalNav-access" class="nav-item" role="presentation">
                        <span class="nav-link"> 
                        Access provided by: 
                        BMJ Group (Online access from BMA House)
                        </span>
                     </li>
                     <li id="globalNav-cmecpd" class="nav-item" role="menuitem">
                        <a class="nav-link" href="https://bestpractice.bmj.com/activity">CME / CPD</a>
                     </li>
                     <li id="globalNav-help" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/8#" id="navbarDropdownMenuLink02" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false"> 
                        Help <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-help-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink02">
                           <span class="material-icons"></span>
                           <ul role="menu">
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/getting-started/" target="_blank">Getting started</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/faq/" target="_blank">FAQs</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/" target="_blank">About CME/CPD</a></li>
                              <li class="dropdown-item"><a href="https://bestpractice.bmj.com/info/contact-us/" target="_blank">Contact us</a></li>
                           </ul>
                        </div>
                     </li>
                     <li id="globalNav-account" class="nav-item dropdown" role="menuitem">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/8#" id="navbarDropdownMenuLink01" class="nav-link dropdown-toggle" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false">
                        <span class="material-icons"></span>&nbsp;
                        <span>stailor@bmj.com</span> 
                        <span class="states">
                        <span class="material-icons"></span>
                        <span class="material-icons"></span>
                        </span>
                        </a>
                        <div id="globalNav-account-options" class="dropdown-menu dropdown-menu-right" aria-labelledby="navbarDropdownMenuLink01">
                           <span class="material-icons"></span>
                           <ul class="list-group" role="menu">
                              <li class="dropdown-item">
                                 <form method="POST" action="https://bestpractice.bmj.com/logout">
                                    <input type="hidden" name="loggedIn" id="loggedIn" value="true">
                                    <button type="submit" value="Log out">
                                    Log out
                                    </button>
                                 </form>
                              </li>
                              <li class="dropdown-item"><a href="https://myaccount.bmj.com/myaccount/account/home-view.html?fwdUrl=https://bestpractice.bmj.com" target="_blank">My details</a></li>
                              <li hidden="hidden" class="dropdown-item"><a href="https://myaccount.bmj.com/myaccount/account/home-view.html#email-matrix-container?fwdUrl=https://bestpractice.bmj.com" target="_blank">My emails</a></li>
                           </ul>
                        </div>
                     </li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem" hidden="hidden"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
         <div id="mainSearch" class="container">
            <div class="row">
               <div class="col-lg-7">
                  <div class="logo-img"><a href="https://bestpractice.bmj.com/"><span class="remove"><abbr title="British Medical Journal">BMJ</abbr> Best Practice</span></a></div>
               </div>
               <div class="col-lg-5">
                  <style type="text/css">
                     #searchBoxWrap .tt-open:before {content: "Recently viewed topics:"; }
                     #searchBoxWrap .tt-label-override:before,
                     #searchBoxWrap .tt-suggested:before {content: "Suggested topics:" !important; }
                  </style>
                  <form id="searchBoxForm" action="https://bestpractice.bmj.com/search" role="search" novalidate="novalidate">
                     <div class="input-group">
                        <div id="searchBoxWrap">
                           <label for="q" class="sr-only">Search</label>
                           <span class="twitter-typeahead" style="position: relative; display: inline-block;">
                              <input id="q" type="text" name="q" placeholder="Search conditions, symptoms..." value="" class="tt-input" autocomplete="off" spellcheck="false" dir="auto" style="position: relative; vertical-align: top;">
                              <pre aria-hidden="true" style="position: absolute; visibility: hidden; white-space: pre; font-family: sans-serif; font-size: 16px; font-style: normal; font-variant: normal; font-weight: 400; word-spacing: 0px; letter-spacing: 0px; text-indent: 0px; text-rendering: auto; text-transform: none;"></pre>
                              <div class="tt-menu" style="position: absolute; top: 100%; left: 0px; z-index: 100; display: none;">
                                 <div class="tt-dataset tt-dataset-0"></div>
                              </div>
                           </span>
                           <button id="mainSearchBtn" type="submit"><span class="material-icons"></span></button>
                        </div>
                     </div>
                  </form>
                  <script>
                     /*<![CDATA[*/
                     
                            <!-- These are required in completion, see BP-232 -->
                            var searchDefaultLanguageCode = "en-gb";
                            var regionName = "GB and ROW";
                            var regionAvailableLanguagesCodes = [{"id":"1","code":"en-gb","displayName":"English"},{"id":"3","code":"pt-br","displayName":"Portugu\u00EAs"},{"id":"5","code":"es-es","displayName":"Espa\u00F1ol"},{"id":"7","code":"ru-ru","displayName":"\u0420\u0443\u0441\u0441\u043A\u0438\u0439"}];
                            var availableLanguages = [];
                     
                            for (i = 0; i < regionAvailableLanguagesCodes.length; i++) {
                                availableLanguages.push(regionAvailableLanguagesCodes[i].code);
                            }
                     /*]]>*/
                  </script>
               </div>
            </div>
         </div>
         <nav id="mainNav" class="navbar navbar-toggleable-md" role="navigation">
            <div class="container">
               <div id="mainNavbarNav">
                  <ul class="navbar-nav" role="menubar">
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/recent-updates"><span class="icon icon-bp-icons-recent-updates"></span><span>Recent updates</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/specialties"><span class="icon icon-bp-icons-specialties"></span><span>Specialties</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/calculators"><span class="icon icon-bp-icons-calculators"></span><span>Calculators</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/patient-leaflets"><span class="icon icon-bp-icons-patient-leaflets"></span><span>Patient leaflets</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/procedural-videos"><span class="icon icon-bp-icons-procedural-videos"></span><span>Procedural videos</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/evidence"><span class="icon icon-bp-icons-evidence"></span><span>Evidence</span></a></li>
                     <li class="nav-item main" role="menuitem"><a class="nav-link" href="https://bestpractice.bmj.com/drugs"><span class="icon icon-bp-icons-drugs"></span><span>Drugs</span></a></li>
                  </ul>
               </div>
            </div>
         </nav>
      </header>
      <main id="tmp" class="container tmp topic main-container" role="main">
         <script type="text/javascript">
            /*<![CDATA[*/ 
            var topicId = 8; 
            var langCode="en-gb"; 
            /*]]>*/
         </script>
         <div id="topicNav" class="container">
            <div class="lang">
               <ul role="menu">
                  <li><a href="https://bestpractice.bmj.com/topics/en-gb/8" class="active">English</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/pt-br/8">Português</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/es-es/8">Español</a></li>
                  <li><a href="https://bestpractice.bmj.com/topics/ru-ru/8">Русский</a></li>
               </ul>
            </div>
            <div id="topicMenuTopBg" style="height: 110px;"></div>
            <div id="topicMenuTopWrap" style="height: 110px;">
               <div id="topicMenuTop" style="height: 110px;">
                  <h1>Acute exacerbation of chronic obstructive pulmonary disease</h1>
                  <div class="pdf-links-nav">
                     <div class="pdf">
                        <a href="https://bestpractice.bmj.com/topics/en-gb/8/pdf/8.pdf" target="_blank">
                        <span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span>
                        </a>
                     </div>
                  </div>
                  <div id="mobileMenu" class="mUp">
                     <a href="https://bestpractice.bmj.com/topics/en-gb/8#" role="button">
                     <span><span class="material-icons"></span> Menu</span>
                     <span><span class="material-icons"></span> Close</span>
                     </a>
                  </div>
                  <ul id="menuLinks" role="menu">
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/8#smenu-0" aria-owns="menu-0">Overview <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/8#smenu-1" aria-owns="menu-1">Theory <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/8#smenu-2" aria-owns="menu-2">Diagnosis <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/8#smenu-3" aria-owns="menu-3">Management <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/8#smenu-4" aria-owns="menu-4">Follow up <span class="material-icons"></span><span class="material-icons"></span></a></li>
                     <li><a href="https://bestpractice.bmj.com/topics/en-gb/8#smenu-5" aria-owns="menu-5">Resources <span class="material-icons"></span><span class="material-icons"></span></a></li>
                  </ul>
               </div>
            </div>
            <div id="topicMenuBottomWrap" style="height: 176px;">
               <nav id="topicMenuBottom" class="mUp" role="navigation" style="height: 176px;">
                  <ul id="menus" role="menubar">
                        <li>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/8/investigations#" class="parent"><span>Overview</span><span class="material-icons"></span><span class="material-icons"></span></a>
                           <ul role="menu" id="menu-0">
                              <li><a href="8_AECOPD_overview_summary.html" id="Summary">Summary</a></li>
                           </ul>
                        </li>
                        <li>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/8/investigations#" class="parent"><span>Theory</span><span class="material-icons"></span><span class="material-icons"></span></a>
                           <ul role="menu" id="menu-1">
                              <li><a href="8_AECOPD_theory_epidemiology.html" id="Epidemiology">Epidemiology</a></li>
                              <li><a href="8_AECOPD_theory_aetiology.html" id="Aetiology">Aetiology</a></li>
                              <li><a href="8_AECOPD_theory_case-history.html" id="Case history">Case history</a></li>
                           </ul>
                        </li>
                        <li>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/8/investigations#" class="parent"><span>Diagnosis</span><span class="material-icons"></span><span class="material-icons"></span></a>
                           <ul role="menu" id="menu-2">
                              <li><a href="8_AECOPD_diagnosis_recommendations.html" id="Recommendations">Recommendations</a></li>
                              <li><a href="8_AECOPD_diagnosis_history_and_exam.html" id="History and exam">History and exam</a></li>
                              <li><a href="8_AECOPD_diagnosis_investigations.html" id="Investigations">Investigations</a></li>
                              <li><a href="8_AECOPD_diagnosis_differentials.html" id="Differentials">Differentials</a></li>
                              <li><a href="8_AECOPD_diagnosis_criteria.html" id="Criteria">Criteria</a></li>
                           </ul>
                        </li>
                        <li>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/8/investigations#" class="parent"><span>Management</span><span class="material-icons"></span><span class="material-icons"></span></a>
                           <ul role="menu" id="menu-3">
                               <li><a href="8_AECOPD_management_recommendations.html" id="Recommendations">Recommendations</a></li>
                              <li><a href="8_AECOPD_management_treatment_algorithm.html" id="Treatment algorithm">Treatment algorithm</a></li>
                              <li><a href="8_AECOPD_management_prevention.html" id="Prevention" class="active">Prevention</a></li>
                              <li><a href="8_AECOPD_management_patient_discussions.html" id="Patient discussions">Patient discussions</a></li>
                           </ul>
                        </li>
                        <li>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/8/investigations#" class="parent"><span>Follow up</span><span class="material-icons"></span><span class="material-icons"></span></a>
                           <ul role="menu" id="menu-4">
                              <li><a href="8_AECOPD_follow_up_monitoring.html" id="Monitoring">Monitoring</a></li>
                              <li><a href="8_AECOPD_follow_up_complications.html" id="Complications">Complications</a></li>
                              <li><a href="8_AECOPD_follow_up_prognosis.html" id="Prognosis">Prognosis</a></li>
                           </ul>
                        </li>
                        <li>
                           <a href="https://bestpractice.bmj.com/topics/en-gb/8/investigations#" class="parent"><span>Resources</span><span class="material-icons"></span><span class="material-icons"></span></a>
                           <ul role="menu" id="menu-5">
                              <li><a href="8_AECOPD_resources_guidelines.html" id="Guidelines">Guidelines</a></li>
                              <li><a href="8_AECOPD_resources_images_videos.html" id="Images and videos">Images and videos</a></li>
                              <li><a href="8_AECOPD_resources_references.html" id="References">References</a></li>
                              <li><a href="8_AECOPD_resources_patient_leaflets.html" id="Patient leaflets">Patient leaflets</a></li>
                              <li><a href="8_AECOPD_resources_evidence.html" id="Evidence">Evidence</a></li>
                           </ul>
                        </li>
                        <li class="mpdf"><a href="https://bestpractice.bmj.com/topics/en-gb/8/pdf/8.pdf" target="_blank"><span class="icon icon-bp-icons-pdf-extra-small-on-white"></span> <span>View PDF</span></a></li>
               </nav>
            </div>
         </div>
         <h2 id="sr-content">Primary prevention</h2>
         <div class="card">
            <div class="card-block">
               <!-- Primary prevention section-->
               <p class="w-75">
                  <!-- col-md-9 -->
                  Given the detrimental impact of COPD exacerbations on the patient, every effort should be made to prevent their occurrence. Previous exacerbation history is a key risk factor for future exacerbations.
                  <span class="reference"> 
                  <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                  <span class="citationText" aria-hidden="true">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]</span> 
                  <span class="citationFullTextUrl" aria-hidden="true">
                  http://goldcopd.org/gold-reports/
                  </span>
                  </span>
                  <span class="reference">
                     <a href="#referencePop55" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[55]</a> 
                     <span class="citationText" aria-hidden="true">
                        Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363
                        <rc-c2d-number data-rc-number=":1128-1138">:1128-1138</rc-c2d-number>
                        .
                     </span>
                     <span class="citationFullTextUrl" aria-hidden="true">
                     http://www.nejm.org/doi/full/10.1056/NEJMoa0909883#t=article
                     </span>
                     <span class="referenceUniqueId" aria-hidden="true">
                     http://www.ncbi.nlm.nih.gov/pubmed/20843247?tool=bestpractice.com
                     </span>
                  </span>
                  People with a high burden of symptoms and history of frequent exacerbations (Global Initiative for Chronic Obstructive Lung Disease [GOLD] group D) are at particular risk of future exacerbations and mortality.
                  <span class="reference"> 
                  <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                  <span class="citationText" aria-hidden="true">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]</span> 
                  <span class="citationFullTextUrl" aria-hidden="true">
                  http://goldcopd.org/gold-reports/
                  </span>
                  </span>
                  <span class="reference"> 
                  <a href="#referencePop79" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[79]</a> 
                  <span class="citationText" aria-hidden="true">Chen CZ, Ou CY, Yu CH, et al. Comparison of global initiative for chronic obstructive pulmonary disease 2013 classification and body mass index, airflow obstruction, dyspnea, and exacerbations index in predicting mortality and exacerbations in elderly adults with chronic obstructive pulmonary disease. J Am Geriatr Soc. 2015;63:244-250.</span> 
                  <span class="referenceUniqueId" aria-hidden="true">
                  http://www.ncbi.nlm.nih.gov/pubmed/25641518?tool=bestpractice.com
                  </span>
                  </span>
                  However, multiple factors impact the risk of subsequent exacerbations and relevant factors vary among individual patients. Following COPD exacerbation, every effort should be made to both identify and intervene in potentially modifiable factors to reduce risk of subsequent exacerbation events. 
               </p>
               <p class="w-75">
                  <!-- col-md-9 -->
                  Trigger avoidance, smoking cessation, and immunisation
               </p>
               <ul class="w-75">
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Avoiding smoke and smoking cessation are the best measures not only to prevent the onset of COPD but also to prevent progression of the severity of COPD.
                        <span class="reference">
                           <a href="#referencePop80" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[80]</a> 
                           <span class="citationText" aria-hidden="true">
                              Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA. 1994;272
                              <rc-c2d-number data-rc-number=":1497-1505">:1497-1505</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/7966841?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop81" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[81]</a> 
                        <span class="citationText" aria-hidden="true">Thabane M; COPD Working Group. Smoking cessation for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-50.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384371/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23074432?tool=bestpractice.com
                        </span>
                        </span>
                        Smoking cessation can also reduce risk of exacerbations,
                        <span class="reference"> 
                        <a href="#referencePop82" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[82]</a> 
                        <span class="citationText" aria-hidden="true">Au DH, Bryson CL, Chien JW, et al. The effects of smoking cessation on the risk of chronic obstructive pulmonary disease exacerbations. J Gen Intern Med. 2009;24:457-463.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2659150/?tool=pubmed
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19194768?tool=bestpractice.com
                        </span>
                        </span>
                        and smoking cessation counselling and treatment is recommended for people with COPD.
                        <span class="reference">
                           <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                           <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1918414
                                 ">=1918414</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                           </span>
                        </span>
                        Patients should also be advised to avoid other potential triggers such as airborne pollutants. More severe COPD is associated with both more frequent and more severe exacerbations.
                        <span class="reference">
                           <a href="#referencePop55" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[55]</a> 
                           <span class="citationText" aria-hidden="true">
                              Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363
                              <rc-c2d-number data-rc-number=":1128-1138">:1128-1138</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.nejm.org/doi/full/10.1056/NEJMoa0909883#t=article
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/20843247?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop84" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[84]</a> 
                           <span class="citationText" aria-hidden="true">
                              McCrory DC, Brown C, Gelfand SE, et al. Management of acute exacerbations of COPD: a summary and appraisal of published evidence. Chest. 2001;119
                              <rc-c2d-number data-rc-number=":1190-1209">:1190-1209</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11296189?tool=bestpractice.com
                           </span>
                        </span>
                        There is evidence that influenza vaccination is effective in preventing complications of COPD,
                        <span class="reference"> 
                        <a href="#referencePop85" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[85]</a> 
                        <span class="citationText" aria-hidden="true">Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397-403.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/10068413?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop86" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[86]</a> 
                           <span class="citationText" aria-hidden="true">
                              Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004;125
                              <rc-c2d-number data-rc-number=":2011-2020">:2011-2020</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/15189916?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop87" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[87]</a> 
                        <span class="citationText" aria-hidden="true">Sehatzadeh S. Influenza and pneumococcal vaccinations for patients with chronic obstructive pulmonary disease (COPD): an evidence-based review. Ont Health Technol Assess Ser. 2012;12:1-64.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384373/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23074431?tool=bestpractice.com
                        </span>
                        </span>
                        particularly among people with severe airflow obstruction.
                        <span class="reference"> 
                        <a href="#referencePop88" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[88]</a> 
                        <span class="citationText" aria-hidden="true">OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser. 2012;12:1-97.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384372/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23074430?tool=bestpractice.com
                        </span>
                        </span>
                        Yearly influenza vaccine is recommended for adults with COPD.
                        <span class="reference">
                           <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                           <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1918414
                                 ">=1918414</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                           </span>
                        </span>
                        The benefits of pneumococcal vaccination in reducing overall morbidity from COPD (including exacerbations) is less clear,
                        <span class="reference">
                           <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                           <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1918414
                                 ">=1918414</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop89" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[89]</a> 
                        <span class="citationText" aria-hidden="true">Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax. 2006;61:189-195.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/16227328?tool=bestpractice.com
                        </span>
                        </span>
                        but the vaccine does reduce the risk of pneumococcal pneumonia.
                        <span class="reference"> 
                        <a href="#referencePop88" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[88]</a> 
                        <span class="citationText" aria-hidden="true">OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser. 2012;12:1-97.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384372/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23074430?tool=bestpractice.com
                        </span>
                        </span>
                        An updated Cochrane review concluded that pneumococcal vaccination in people with COPD reduced the chance of an acute exacerbation and provided some protection against community-acquired pneumonia.
                        <span class="reference"> 
                        <a href="#referencePop90" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[90]</a> 
                        <span class="citationText" aria-hidden="true">Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jan 24;1:CD001390.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001390.pub4/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/28116747?tool=bestpractice.com
                        </span>
                        </span>
                        Pneumococcal vaccinations, PCV13 (13-valent conjugated pneumococcal vaccine) and PPSV23 (23-valent pneumococcal polysaccharide vaccine), are recommended for all patients over 65 years of age. The PPSV23 is also recommended for younger patients with COPD who have comorbidities such as chronic heart or lung disease.
                        <span class="reference"> 
                        <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                        <span class="citationText" aria-hidden="true">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://goldcopd.org/gold-reports/
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                           <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1918414
                                 ">=1918414</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                           </span>
                        </span>
                        The indications and benefits of vaccination against influenza virus, and 
                        <i>Streptococcus pneumoniae</i>
                        , should be discussed with the patient.
                        <span class="reference"> 
                        <a href="#referencePop85" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[85]</a> 
                        <span class="citationText" aria-hidden="true">Nichol KL, Baken L, Nelson A. Relation between influenza vaccination and outpatient visits, hospitalization, and mortality in elderly persons with chronic lung disease. Ann Intern Med. 1999;130:397-403.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/10068413?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop86" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[86]</a> 
                           <span class="citationText" aria-hidden="true">
                              Wongsurakiat P, Maranetra KN, Wasi C, et al. Acute respiratory illness in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest. 2004;125
                              <rc-c2d-number data-rc-number=":2011-2020">:2011-2020</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/15189916?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop91" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[91]</a> 
                           <span class="citationText" aria-hidden="true">
                              Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164
                              <rc-c2d-number data-rc-number=":1618-1623">:1618-1623</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11719299?tool=bestpractice.com
                           </span>
                        </span>
                     </p>
                  </li>
               </ul>
               <p class="w-75">
                  <!-- col-md-9 -->
                  Pharmacotherapy
               </p>
               <ul class="w-75">
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Once the patient has stabilised following treatment for an exacerbation, the patient’s maintenance medications should be reviewed and consideration should be given to adjusting the medications following exacerbations, with the goal of reducing the risk and/or severity of future episodes,
                        <span class="reference">
                           <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                           <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1918414
                                 ">=1918414</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                           </span>
                        </span>
                        and use of medications according to evidence-based guidelines.
                        <span class="reference"> 
                        <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                        <span class="citationText" aria-hidden="true">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://goldcopd.org/gold-reports/
                        </span>
                        </span>
                        The use of long-acting beta-2 agonists and long-acting anticholinergic medicines has been associated with a decreased frequency of exacerbations.
                        <span class="reference">
                           <a href="#referencePop92" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[92]</a> 
                           <span class="citationText" aria-hidden="true">
                              Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163
                              <rc-c2d-number data-rc-number=":1087-1092">:1087-1092</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11316640?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop93" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[93]</a> 
                        <span class="citationText" aria-hidden="true">Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17314337?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop94" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[94]</a> 
                        <span class="citationText" aria-hidden="true">Niewoehner DE, Rice K, Cote C, et al. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a once-daily inhaled anticholinergic bronchodilator: a randomized trial. Ann Intern Med. 2005;143:317-326.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/16144890?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop95" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[95]</a> 
                        <span class="citationText" aria-hidden="true">Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/10208192?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop96" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[96]</a> 
                        <span class="citationText" aria-hidden="true">Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J. 2002;19:217-224.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://erj.ersjournals.com/content/19/2/217.long
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/11866001?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop97" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[97]</a> 
                        <span class="citationText" aria-hidden="true">Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1746668/?tool=pubmed
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/12728159?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop98" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[98]</a> 
                           <span class="citationText" aria-hidden="true">
                              Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359
                              <rc-c2d-number data-rc-number=":1543-1554">:1543-1554</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://content.nejm.org/cgi/content/full/359/15/1543
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18836213?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop99" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[99]</a> 
                        <span class="citationText" aria-hidden="true">Tashkin DP. Preventing and managing exacerbations in COPD--critical appraisal of the role of tiotropium. Int J Chron Obstruct Pulmon Dis. 2010;5:41-53.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2846152/?tool=pubmed
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20368910?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop100" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[100]</a> 
                        <span class="citationText" aria-hidden="true">Halpin D, Menjoge S, Viel K. Patient-level pooled analysis of the effect of tiotropium on COPD exacerbations and related hospitalisations. Prim Care Respir J. 2009;18:106-113.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19407916?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop101" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[101]</a> 
                        <span class="citationText" aria-hidden="true">Cooper CB, Anzueto A, Decramer M, et al. Tiotropium reduces risk of exacerbations irrespective of previous use of inhaled anticholinergics in placebo-controlled clinical trials. Int J Chron Obstruct Pulmon Dis. 2011;6:269-275.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3152465/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21845038?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop102" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[102]</a> 
                           <span class="citationText" aria-hidden="true">
                              Morice AH, Celli B, Kesten S, et al. COPD in young patients: a pre-specified analysis of the four-year trial of tiotropium (UPLIFT). Respir Med. 2010;104
                              <rc-c2d-number data-rc-number=":1659-1667">:1659-1667</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/20724131?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop103" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[103]</a> 
                        <span class="citationText" aria-hidden="true">Van den BA, Gailly J, Neyt M. Does tiotropium lower exacerbation and hospitalization frequency in COPD patients: results of a meta-analysis. BMC Pulm Med. 2010;10:50.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2955630/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20858226?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop104" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[104]</a> 
                        <span class="citationText" aria-hidden="true">Wang J, Nie B, Xiong W, et al. Effect of long-acting beta-agonists on the frequency of COPD exacerbations: a meta-analysis. J Clin Pharm Ther. 2012;37:204-211.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21740451?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop105" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[105]</a> 
                        <span class="citationText" aria-hidden="true">Yohannes AM, Willgoss TG, Vestbo J. Tiotropium for treatment of stable COPD: a meta-analysis of clinically relevant outcomes. Resp Care. 2011;56:477-487.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://rc.rcjournal.com/content/56/4/477.short
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21255503?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop106" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[106]</a> 
                        <span class="citationText" aria-hidden="true">Decramer ML, Hanania NA, Lötvall JO, et al. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:53-64.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558319/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23378756?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop107" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[107]</a> 
                        <span class="citationText" aria-hidden="true">Mahler DA, Buhl R, Lawrence D, et al. Efficacy and safety of indacaterol and tiotropium in COPD patients according to dyspnoea severity. Pulm Pharmacol Ther. 2013;26:348-355.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23434446?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop108" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[108]</a> 
                        <span class="citationText" aria-hidden="true">Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(10):CD010177.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010177.pub2/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24127118?tool=bestpractice.com
                        </span>
                        </span>
                        The long-acting anticholinergic agent tiotropium bromide may be more effective than the long-acting beta-2-agonist salmeterol in preventing exacerbations,
                        <span class="reference">
                           <a href="#referencePop109" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[109]</a> 
                           <span class="citationText" aria-hidden="true">
                              Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N Engl J Med. 2011;364
                              <rc-c2d-number data-rc-number=":1093-1103">:1093-1103</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/21428765?tool=bestpractice.com
                           </span>
                        </span>
                        particularly among people with moderate-severity airflow obstruction.
                        <span class="reference"> 
                        <a href="#referencePop110" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[110]</a> 
                        <span class="citationText" aria-hidden="true">Vogelmeier C, Fabbri LM, Rabe KF, et al. Effect of tiotropium vs. salmeterol on exacerbations: GOLD II and maintenance therapy naïve patients. Respir Med. 2013;107:75-83.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23102611?tool=bestpractice.com
                        </span>
                        </span>
                        The novel Respimat mist delivery system for tiotropium must, however, be used with caution, given that its use has been associated with a higher mortality rate.
                        <span class="reference"> 
                        <a href="#referencePop111" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[111]</a> 
                        <span class="citationText" aria-hidden="true">Beasley R, Singh S, Loke YK, et al. Call for worldwide withdrawal of tiotropium Respimat mist inhaler. BMJ. 2012;345:e7390.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23144209?tool=bestpractice.com
                        </span>
                        </span>
                        The once-daily long-acting inhaled beta-2 agonist indacaterol is also effective in improving health status and reducing symptoms and exacerbations in COPD.
                        <span class="reference"> 
                        <a href="#referencePop112" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[112]</a> 
                        <span class="citationText" aria-hidden="true">Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20522841?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop113" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[113]</a> 
                           <span class="citationText" aria-hidden="true">Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a long-acting beta2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. 2011;140:68-75.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1088000
                                 ">=1088000</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/21349928?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop114" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[114]</a> 
                        <span class="citationText" aria-hidden="true">Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://ajrccm.atsjournals.org/content/182/2/155.long
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20463178?tool=bestpractice.com
                        </span>
                        </span>
                        Another once-daily beta-2-agonist, olodaterol, has been approved for use in some countries.
                        <span class="reference"> 
                        <a href="#referencePop115" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[115]</a> 
                        <span class="citationText" aria-hidden="true">van Noord JA, Smeets JJ, Drenth BM, et al. 24-hour bronchodilation following a single dose of the novel β(2)-agonist olodaterol in COPD. Pulm Pharmacol Ther. 2011;24:666-672.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21839850?tool=bestpractice.com
                        </span>
                        </span>
                        Aclidinium bromide, a novel long-acting muscarinic antagonist, is also an effective bronchodilator that improves lung function, reduces symptoms, and reduces severe exacerbations requiring hospitalisation.
                        <span class="reference"> 
                        <a href="#referencePop116" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[116]</a> 
                        <span class="citationText" aria-hidden="true">Jones PW, Rennard SI, Agusti A, et al. Efficacy and safety of once-daily aclidinium in chronic obstructive pulmonary disease. Respir Res. 2011;12:55.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3098801/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21518460?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop117" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[117]</a> 
                           <span class="citationText" aria-hidden="true">
                              Frampton JE. Aclidinium: in chronic obstructive pulmonary disease. Drugs. 2012;72
                              <rc-c2d-number data-rc-number=":1999-2011">:1999-2011</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23046206?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop118" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[118]</a> 
                        <span class="citationText" aria-hidden="true">Ni H, Soe Z, Moe S. Aclidinium bromide for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(9):CD010509.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010509.pub2/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/25234126?tool=bestpractice.com
                        </span>
                        </span>
                        Neither class of agent poses substantial increased risk of adverse cardiovascular events.
                        <span class="reference"> 
                        <a href="#referencePop106" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[106]</a> 
                        <span class="citationText" aria-hidden="true">Decramer ML, Hanania NA, Lötvall JO, et al. The safety of long-acting β2-agonists in the treatment of stable chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2013;8:53-64.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3558319/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23378756?tool=bestpractice.com
                        </span>
                        </span>
                        Combination dual-class bronchodilator therapy confers greater benefits on lung function than either individual class (long-acting beta-2-agonist or long-acting anticholinergic) alone.
                        <span class="reference"> 
                        <a href="#referencePop119" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[119]</a> 
                        <span class="citationText" aria-hidden="true">Wang J, Jin D, Zuo P, et al. Comparison of tiotropium plus formoterol to tiotropium alone in stable chronic obstructive pulmonary disease: a meta-analysis. Respirology. 2011;16:350-358.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21138499?tool=bestpractice.com
                        </span>
                        </span>
                        However, it remains unclear whether a combination of dual-class bronchodilator therapy is more effective than long-acting antimuscarinic agents alone for reducing exacerbations.
                        <span class="reference"> 
                        <a href="#referencePop120" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[120]</a> 
                        <span class="citationText" aria-hidden="true">Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind, parallel-group study. Lancet Respir Med. 2013;1:199-209.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24429126?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                        [ <img src="/images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                        </a>
                        <span class="ccaTitle" aria-hidden="true">In people with chronic obstructive pulmonary disease, what are the effects of combining long-acting beta2-agonists and tiotropium compared with either drug alone?</span>
                        <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1160/full</span>
                        <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                        </span>
                        Novel combinations of a long-acting beta-2 agonist with a long-acting muscarinic antagonist (i.e., vilanterol/umeclidinium)
                        <span class="reference"> 
                        <a href="#referencePop121" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[121]</a> 
                        <span class="citationText" aria-hidden="true">National Horizon Scanning Centre. Umeclidinium and vilanterol for chronic obstructive pulmonary disease. February 2012. http://www.hsc.nihr.ac.uk (last accessed 28 December 2015).</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.hsric.nihr.ac.uk/topics/umeclidinium-and-vilanterol-for-chronic-obstructive-pulmonary-disease/
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop122" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[122]</a> 
                           <span class="citationText" aria-hidden="true">
                              Bateman ED, Ferguson GT, Barnes N, et al. Dual bronchodilation with QVA149 versus single bronchodilator therapy: the SHINE study. Eur Respir J. 2013;42
                              <rc-c2d-number data-rc-number=":1484-1494">:1484-1494</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3844137/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23722616?tool=bestpractice.com
                           </span>
                        </span>
                        are currently under investigation, but their efficacy in reducing the frequency and/or severity of exacerbations is as yet unknown.
                        <span class="reference">
                           <a href="#referencePop123" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[123]</a> 
                           <span class="citationText" aria-hidden="true">
                              Donohue JF, Maleki-Yazdi MR, Kilbride S, et al. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107
                              <rc-c2d-number data-rc-number=":1538-1546">:1538-1546</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://www.resmedjournal.com/article/S0954-6111%2813
                              <rc-c2d-number data-rc-number="%2900213-8">%2900213-8</rc-c2d-number>
                              /fulltext
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23830094?tool=bestpractice.com
                           </span>
                        </span>
                        Inhaled corticosteroids have been shown to decrease the frequency of exacerbations and decrease healthcare utilisation for respiratory illnesses.
                        <span class="reference">
                           <a href="#referencePop124" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[124]</a> 
                           <span class="citationText" aria-hidden="true">
                              Burge PS, Calverley PM, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ. 2000;320
                              <rc-c2d-number data-rc-number=":1297-1303">:1297-1303</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=pubmed&amp;pubmedid
                              <rc-c2d-number data-rc-number="=10807619
                                 ">=10807619</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/10807619?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop125" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[125]</a> 
                           <span class="citationText" aria-hidden="true">
                              Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med. 2000;343
                              <rc-c2d-number data-rc-number=":1902-1909">:1902-1909</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.nejm.org/doi/full/10.1056/NEJM200012283432601#t=article
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/11136260?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop126" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[126]</a> 
                        <span class="citationText" aria-hidden="true">Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545-555.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.annals.org/content/146/8/545.full.pdf
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17310045?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop127" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[127]</a> 
                        <span class="citationText" aria-hidden="true">Alsaeedi A, Sin DD, McAlister FA. The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: a systematic review of randomized placebo-controlled trials. Am J Med. 2002;113:59-65.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/12106623?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop128" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[128]</a> 
                        <span class="citationText" aria-hidden="true">Spencer S, Karner C, Cates CJ, et al. Inhaled corticosteroids versus long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(12):CD007033.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007033.pub3/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/22161409?tool=bestpractice.com
                        </span>
                        </span>
                        Inhaled corticosteroids should not be used as monotherapy in COPD; their use should be considered as additional therapy for people with exacerbations not controlled with long-acting bronchodilators alone.
                        <span class="reference"> 
                        <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                        <span class="citationText" aria-hidden="true">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://goldcopd.org/gold-reports/
                        </span>
                        </span>
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        The combination of inhaled corticosteroids and long-acting beta-2 agonists appears more effective than either agent alone to decrease the frequency of episodes in people with more severe COPD.
                        <span class="reference"> 
                        <a href="#referencePop93" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[93]</a> 
                        <span class="citationText" aria-hidden="true">Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17314337?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop129" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[129]</a> 
                        <span class="citationText" aria-hidden="true">Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/12570112?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop130" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[130]</a> 
                        <span class="citationText" aria-hidden="true">Calverley PM, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912-919.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://erj.ersjournals.com/cgi/content/full/22/6/912
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/14680078?tool=bestpractice.com
                        </span>
                        </span>
                        In patients with moderate to severe COPD, treatment with salmeterol plus fluticasone propionate reduces the rate of exacerbations and slows the progressive worsening of FEV1.
                        <span class="reference">
                           <a href="#referencePop131" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[131]</a> 
                           <span class="citationText" aria-hidden="true">
                              Ferguson GT, Anzueto A, Fei R, et al. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations. Respir Med. 2008;102
                              <rc-c2d-number data-rc-number=":1099-1108">:1099-1108</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18614347?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop132" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[132]</a> 
                        <span class="citationText" aria-hidden="true">Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med. 2008;178:332-338.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/18511702?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop133" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[133]</a> 
                        <span class="citationText" aria-hidden="true">Anzueto A, Ferguson GT, Feldman G, et al. Effect of fluticasone propionate/salmeterol (250/50) on COPD exacerbations and impact on patient outcomes. COPD. 2009;6:320-329.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19863361?tool=bestpractice.com
                        </span>
                        </span>
                        Importantly, withdrawal of the inhaled corticosteroid component of combination therapy led to deterioration in lung function and worsened symptoms among patients who had two or more exacerbations in the previous year.
                        <span class="reference"> 
                        <a href="#referencePop134" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[134]</a> 
                        <span class="citationText" aria-hidden="true">Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial. Thorax. 2005;60:480-487.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1747438/?tool=pubmed
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/15923248?tool=bestpractice.com
                        </span>
                        </span>
                        A subsequent large parallel group study among patients with severe COPD and history of previous exacerbation showed similar risk of moderate or severe exacerbation among people who withdrew the inhaled corticosteroid from triple combination treatment gradually over a 12-week period, compared with controls who did not; inhaled corticosteroid withdrawal was, however, associated with a greater reduction in trough FEV1 at 18 weeks of follow-up.
                        <span class="reference">
                           <a href="#referencePop135" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[135]</a> 
                           <span class="citationText" aria-hidden="true">
                              Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med. 2014;371
                              <rc-c2d-number data-rc-number=":1285-1294">:1285-1294</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.nejm.org/doi/full/10.1056/NEJMoa1407154#t=article
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25196117?tool=bestpractice.com
                           </span>
                        </span>
                        Also, an increased risk of pneumonia has been reported following long-term use of inhaled corticosteroids and inhaled corticosteroid/beta-2 agonist combination therapy.
                        <span class="reference"> 
                        <a href="#referencePop93" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[93]</a> 
                        <span class="citationText" aria-hidden="true">Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17314337?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop136" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[136]</a> 
                        <span class="citationText" aria-hidden="true">Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 May 31;(5):CD007891.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007891.pub3/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23728670?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop137" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[137]</a> 
                        <span class="citationText" aria-hidden="true">Crim C, Calverley PM, Anderson JA, et al. Pneumonia risk in COPD patients receiving inhaled corticosteroids alone or in combination: TORCH study results. Eur Respir J. 2009;34:641-647.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://erj.ersjournals.com/content/34/3/641.long
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19443528?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop138" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[138]</a> 
                        <span class="citationText" aria-hidden="true">Singh S, Loke YK. An overview of the benefits and drawbacks of inhaled corticosteroids in chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis. 2010;5:189-195.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2921686/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20714372?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop139" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[139]</a> 
                           <span class="citationText" aria-hidden="true">Calverley PM, Stockley RA, Seemungal TA, et al. Reported pneumonia in patients with COPD: findings from the INSPIRE study. Chest. 2011;139:505-512.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1087764
                                 ">=1087764</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/20576732?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop140" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[140]</a> 
                        <span class="citationText" aria-hidden="true">Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):CD010115.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010115.pub2/abstract
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24615270?tool=bestpractice.com
                        </span>
                        </span>
                        This increased risk of pneumonia is not accompanied by a clear increase in mortality risk.
                        <span class="reference"> 
                        <a href="#referencePop140" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[140]</a> 
                        <span class="citationText" aria-hidden="true">Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):CD010115.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010115.pub2/abstract
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/24615270?tool=bestpractice.com
                        </span>
                        </span>
                        Currently, there are limited but encouraging data on the concurrent use of inhaled corticosteroids, long-acting beta-2 agonists, and long-acting anticholinergic medicines.
                        <span class="reference">
                           <a href="#referencePop98" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[98]</a> 
                           <span class="citationText" aria-hidden="true">
                              Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med. 2008;359
                              <rc-c2d-number data-rc-number=":1543-1554">:1543-1554</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://content.nejm.org/cgi/content/full/359/15/1543
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18836213?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop126" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[126]</a> 
                        <span class="citationText" aria-hidden="true">Aaron SD, Vandemheen KL, Fergusson D, et al. Tiotropium in combination with placebo, salmeterol, or fluticasone-salmeterol for treatment of chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med. 2007;146:545-555.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.annals.org/content/146/8/545.full.pdf
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17310045?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop141" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[141]</a> 
                        <span class="citationText" aria-hidden="true">Tashkin DP, Littner M, Andrews CP, et al. Concomitant treatment with nebulized formoterol and tiotropium in subjects with COPD: a placebo-controlled trial. Respir Med. 2008;102:479-487.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/18258423?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop142" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[142]</a> 
                           <span class="citationText" aria-hidden="true">
                              Tashkin DP, Rennard SI, Martin P, et al. Efficacy and safety of budesonide and formoterol in one pressurized metered-dose inhaler in patients with moderate to very severe chronic obstructive pulmonary disease: results of a 6-month randomized clinical trial. Drugs. 2008;68
                              <rc-c2d-number data-rc-number=":1975-2000">:1975-2000</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18778120?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop143" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[143]</a> 
                        <span class="citationText" aria-hidden="true">Wedzicha JA, Calverley PM, Seemungal TA, et al. The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol/fluticasone propionate or tiotropium bromide. Am J Respir Crit Care Med. 2008;177:19-26.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/17916806?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop144" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[144]</a> 
                        <span class="citationText" aria-hidden="true">Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:741-750.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19644045?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop145" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[145]</a> 
                        <span class="citationText" aria-hidden="true">Gaebel K, McIvor RA, Xie F, et al. Triple therapy for the management of COPD: a review. COPD. 2011;8:206-243.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21513437?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop146" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[146]</a> 
                        <span class="citationText" aria-hidden="true">Karner C, Cates CJ. The effect of adding inhaled corticosteroids to tiotropium and long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011;(9):CD009039.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD009039.pub2/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21901729?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop147" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[147]</a> 
                        <span class="citationText" aria-hidden="true">Rojas-Reyes MX, García Morales OM, Dennis RJ, Karner C. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008532.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008532.pub3/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/27271056?tool=bestpractice.com
                        </span>
                        </span>
                        While long-acting beta-2 agonists, anticholinergics, and inhaled corticosteroids are all helpful, the optimal choice of medications to reduce exacerbations while minimising potential adverse events remains somewhat uncertain,
                        <span class="reference"> 
                        <a href="#referencePop136" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[136]</a> 
                        <span class="citationText" aria-hidden="true">Welsh EJ, Cates CJ, Poole P. Combination inhaled steroid and long-acting beta2-agonist versus tiotropium for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013 May 31;(5):CD007891.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007891.pub3/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23728670?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop148" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[148]</a> 
                        <span class="citationText" aria-hidden="true">Baker WL, Baker EL, Coleman CI. Pharmacologic treatments for chronic obstructive pulmonary disease: a mixed-treatment comparison meta-analysis. Pharmacotherapy. 2009;29:891-905.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19637942?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop149" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[149]</a> 
                           <span class="citationText" aria-hidden="true">
                              Rodrigo GJ, Castro-Rodriguez JA, Plaza V. Safety and efficacy of combined long-acting beta-agonists and inhaled corticosteroids vs long-acting beta-agonists monotherapy for stable COPD: a systematic review. Chest. 2009;136
                              <rc-c2d-number data-rc-number=":1029-1038">:1029-1038</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/19633090?tool=bestpractice.com
                           </span>
                        </span>
                        and the impact of triple-class therapy as compared with dual-agent combination therapy or anticholinergic therapy alone on long-term outcomes such as mortality or hospitalisations is as yet unclear.
                        <span class="reference"> 
                        <a href="#referencePop147" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[147]</a> 
                        <span class="citationText" aria-hidden="true">Rojas-Reyes MX, García Morales OM, Dennis RJ, Karner C. Combination inhaled steroid and long-acting beta₂-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Jun 6;(6):CD008532.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD008532.pub3/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/27271056?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop150" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[150]</a> 
                        <span class="citationText" aria-hidden="true">Hanania NA, Crater GD, Morris AN, et al. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med. 2012;106:91-101.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/22040533?tool=bestpractice.com
                        </span>
                        </span>
                        Novel combination therapies including fluticasone/vilanterol and indacaterol/glycopyrronium bromide are emerging, and their impact on exacerbations of COPD is currently being studied.
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Treatment of patients with intermittent doses of macrolide,
                        <span class="reference"> 
                        <a href="#referencePop151" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[151]</a> 
                        <span class="citationText" aria-hidden="true">Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med. 2011; 365: 689-698.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21864166?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop152" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[152]</a> 
                        <span class="citationText" aria-hidden="true">Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013;107:637-648.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23352223?tool=bestpractice.com
                        </span>
                        </span>
                        the fluoroquinolone moxifloxacin,
                        <span class="reference"> 
                        <a href="#referencePop153" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[153]</a> 
                        <span class="citationText" aria-hidden="true">Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res. 2010;11:10.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2834642/?tool=pubmed
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20109213?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop154" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[154]</a> 
                           <span class="citationText" aria-hidden="true">
                              Miravitlles M, Marín A, Monsó E, et al. Efficacy of moxifloxacin in the treatment of bronchial colonisation in COPD. Eur Respir J. 2009;34
                              <rc-c2d-number data-rc-number=":1066-1071">:1066-1071</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://erj.ersjournals.com/content/34/5/1066.long
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/19386683?tool=bestpractice.com
                           </span>
                        </span>
                        phosphodiesterase inhibitors
                        <span class="reference"> 
                        <a href="#referencePop155" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[155]</a> 
                        <span class="citationText" aria-hidden="true">Rennard SI, Schachter N, Strek M, et al. Cilomilast for COPD:results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest. 2006;129:56-66.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/16424413?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop156" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[156]</a> 
                        <span class="citationText" aria-hidden="true">Rabe KF, Bateman ED, O'Donnell D, et al. Roflumilast - an oral anti-inflammatory treatment for chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2005;366:563-571.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/16099292?tool=bestpractice.com
                        </span>
                        </span>
                        such as roflumilast, or statins
                        <span class="reference"> 
                        <a href="#referencePop157" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[157]</a> 
                        <span class="citationText" aria-hidden="true">Mortensen EM, Copeland LA, Pugh MJ, et al. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir Res. 2009;10:45.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19493329?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference">
                           <a href="#referencePop158" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[158]</a> 
                           <span class="citationText" aria-hidden="true">
                              Blamoun AI, Batty GN, DeBari VA, et al. Statins may reduce episodes of exacerbation and the requirement for intubation in patients with COPD: evidence from a retrospective cohort study. Int J Clin Pract. 2008;62
                              <rc-c2d-number data-rc-number=":1373-1378">:1373-1378</rc-c2d-number>
                              .
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18422598?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop159" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[159]</a> 
                        <span class="citationText" aria-hidden="true">Janda S, Park K, FitzGerald JM, et al. Statins in COPD: a systematic review. Chest. 2009;136:734-743.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/19376844?tool=bestpractice.com
                        </span>
                        </span>
                        can also decrease the frequency, severity, and/or duration of COPD exacerbations. The short-term use of prophylactic antibiotics can reduce the rate and number of exacerbations of COPD or chronic bronchitis,
                        <span class="reference"> 
                        <a href="#referencePop160" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[160]</a> 
                        <span class="citationText" aria-hidden="true">Lee JS, Park DA, Hong Y, et al. Systematic review and meta-analysis of prophylactic antibiotics in COPD and/or chronic bronchitis. Int J Tuberc Lung Dis. 2013;17:153-162.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23317949?tool=bestpractice.com
                        </span>
                        </span>
                        and preventative treatment with macrolides can lead to healthcare cost savings.
                        <span class="reference"> 
                        <a href="#referencePop152" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[152]</a> 
                        <span class="citationText" aria-hidden="true">Simoens S, Laekeman G, Decramer M. Preventing COPD exacerbations with macrolides: a review and budget impact analysis. Respir Med. 2013;107:637-648.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/23352223?tool=bestpractice.com
                        </span>
                        </span>
                        Daily azithromycin therapy was most effective in reducing exacerbations requiring both antibiotic and steroid treatment, and risk reduction was greatest among people of older age and milder GOLD grade; notably, no significant reduction of exacerbation risk was found among current smokers.
                        <span class="reference">
                           <a href="#referencePop161" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[161]</a> 
                           <span class="citationText" aria-hidden="true">
                              Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in response to daily azithromycin therapy. Am J Respir Crit Care Med. 2014;189
                              <rc-c2d-number data-rc-number=":1503-1508">:1503-1508</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226018/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/24779680?tool=bestpractice.com
                           </span>
                        </span>
                        The impact of long-term use of intermittent (e.g., three-times weekly) macrolides or other prophylactic antibiotics on the development of antibiotic-resistant pathogens and related COPD exacerbations is as yet unknown but is of potential concern. Phosphodiesterase-4 (PDE4) inhibitor therapy is commonly associated with gastrointestinal upset, abdominal pain, weight loss, and other side effects; individual patient tolerance of these agents varies. Importantly, existing studies suggest that the PDE4 inhibitor roflumilast reduced exacerbations among patients with severe airflow obstruction with clinical features of chronic bronchitis (including sputum production and cough), but not among those with a predominance of emphysema without chronic bronchitis features.
                        <span class="reference"> 
                        <a href="#referencePop162" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[162]</a> 
                        <span class="citationText" aria-hidden="true">Rennard S, Calverley PM, Goehring PMA, et al. Reduction of exacerbations by the PDE4 inhibitor roflumilast—the importance of defining different subsets of patients with COPD. Respir Res. 2011;12:18.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3040135/
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21272339?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop163" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[163]</a> 
                        <span class="citationText" aria-hidden="true">Taegtmeyer AB, Leuppi JD, Kullak-Ublick GA. Roflumilast: a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD. Swiss Med Wkly. 2012;142:w13628.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/22833385?tool=bestpractice.com
                        </span>
                        </span>
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Oral mucolytics such as N-acetylcysteine may offer benefit in exacerbation reduction, particularly among people with moderate to severe COPD and or history of two or more exacerbations in the previous 2 years, but their role remains controversial.
                        <span class="reference">
                           <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                           <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://journal.publications.chestnet.org/article.aspx?articleid
                              <rc-c2d-number data-rc-number="=1918414
                                 ">=1918414</rc-c2d-number>
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                           </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop164" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[164]</a> 
                        <span class="citationText" aria-hidden="true">Davies L, Calverley PM. The evidence for the use of oral mucolytic agents in chronic obstructive pulmonary disease (COPD). Br Med Bull. 2010;93:217-227.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://bmb.oxfordjournals.org/content/93/1/217.long
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20031934?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop165" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[165]</a> 
                        <span class="citationText" aria-hidden="true">Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2015;(7):CD001287.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD001287.pub5/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/26222376?tool=bestpractice.com
                        </span>
                        </span>
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Alpha-1-antitrypsin augmentation therapy may reduce the frequency of exacerbations for selected people with documented alpha-1-antitrypsin deficiency as the aetiology of their COPD.
                        <span class="reference"> 
                        <a href="#referencePop166" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[166]</a> 
                        <span class="citationText" aria-hidden="true">Kueppers F. The role of augmentation therapy in alpha-1 antitrypsin deficiency. Curr Med Res Opin. 2011;27:579-588.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/21226542?tool=bestpractice.com
                        </span>
                        </span>
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Beta-blockers are often withheld from patients with COPD due to concerns regarding precipitation of exacerbations and bronchospasm. However, cardiovascular disease is a common comorbidity of COPD, and many patients have cardiovascular indications for beta-blocker therapy. Current data suggest that cardioselective beta-blockers are not only safe and effective in patients with COPD, but may reduce exacerbation risk and mortality.
                        <span class="reference"> 
                        <a href="#referencePop167" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[167]</a> 
                        <span class="citationText" aria-hidden="true">Salpeter SR, Ormiston TM, Salpeter EE. Cardioselective beta-blockers for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2005;(4):CD003566.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD003566.pub2/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/16235327?tool=bestpractice.com
                        </span>
                        </span>
                        <span class="reference"> 
                        <a href="#referencePop168" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[168]</a> 
                        <span class="citationText" aria-hidden="true">Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med. 2010;170:880-887.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://archinte.jamanetwork.com/article.aspx?articleid=415954
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20498416?tool=bestpractice.com
                        </span>
                        </span>
                        Therefore, beta-blockers should not be withheld from patients with COPD who have cardiovascular indications for their use.
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Some data suggest that an oral 
                        <i>Haemophilus influenzae</i>
                        vaccine may help reduce recurrent exacerbations of chronic bronchitis in selected patients;
                        <span class="reference"> 
                        <a href="#referencePop169" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[169]</a> 
                        <span class="citationText" aria-hidden="true">Foxwell AR, Cripps AW, Dear KB. Haemophilus influenzae oral whole cell vaccination for preventing acute exacerbations of chronic bronchitis. Cochrane Database Syst Rev. 2010;(10):CD001958.</span> 
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/20927727?tool=bestpractice.com
                        </span>
                        </span>
                        however, one Cochrane review analysis demonstrated that oral 
                        <i>H influenzae</i>
                        vaccine did not significantly reduce the number or severity of exacerbations.
                        <span class="reference"> 
                        <a href="#referencePop170" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[170]</a> 
                        <span class="citationText" aria-hidden="true">Teo E, Lockhart K, Purchuri SN, et al. Haemophilus influenzae oral vaccination for preventing acute exacerbations of chronic bronchitis and chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2017 Jun 19;6:CD010010.</span> 
                        <span class="citationFullTextUrl" aria-hidden="true">
                        http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD010010.pub3/full
                        </span>
                        <span class="referenceUniqueId" aria-hidden="true">
                        http://www.ncbi.nlm.nih.gov/pubmed/28626902?tool=bestpractice.com
                        </span>
                        </span>
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Oral 
                        <i>Haemophilus</i>
                        vaccines are not formally recommended in existing guidelines.
                        <span class="reference">
                           <a href="#referencePop31" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[31]</a> 
                           <span class="citationText" aria-hidden="true">Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections - full version. Clini Microbiol Infect. 2011;17(suppl 6):E1-E59.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                              http://onlinelibrary.wiley.com/doi/10.1111/j
                              <rc-c2d-number data-rc-number=".1469-0691">.1469-0691</rc-c2d-number>
                              .2011.03672.x/full
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/21951385?tool=bestpractice.com
                           </span>
                        </span>
                        Prophylactic antibiotics to prevent exacerbations are also not recommended.
                     </p>
                  </li>
                  <li>
                     <p class="w-75">
                        <!-- col-md-9 -->
                        Although retrospective studies suggested that statins might decrease the rate and severity of exacerbations, one large prospective randomised controlled trial of simvastatin versus placebo did not show a reduction in exacerbation rates or time to first exacerbation among people with history of COPD exacerbation requiring accident and emergency department visit or hospitalisation in the year prior to study enrolment.
                        <span class="reference">
                           <a href="#referencePop171" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[171]</a> 
                           <span class="citationText" aria-hidden="true">
                              Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N Engl J Med. 2014;370
                              <rc-c2d-number data-rc-number=":2201-2210">:2201-2210</rc-c2d-number>
                              .
                           </span>
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4375247/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/24836125?tool=bestpractice.com
                           </span>
                        </span>
                     </p>
                  </li>
               </ul>
            </div>
         </div>
         <h2>Secondary prevention</h2>
         <div class="card">
               <div class="card-block">
                  <!-- Secondary prevention section-->
                  <p class="w-75">
                     <!-- col-md-9 -->
                     Pulmonary rehabilitation and disease-management programmes
                  </p>
                  <ul class="w-75">
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Patients who are non-compliant with their medicine regimens may develop worsening of signs and symptoms associated with COPD. It is important to discuss and determine adherence with medications in patients presenting with acute exacerbations.
                           <span class="reference"> 
                           <a href="#referencePop292" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[292]</a> 
                           <span class="citationText" aria-hidden="true">Gross N, Levin D. Primary care of the patient with chronic obstructive pulmonary disease-part 2: pharmacologic treatment across all stages of disease. Am J Med. 2008;121(suppl 7):S13-S24.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18558103?tool=bestpractice.com
                           </span>
                           </span>
                           Failure to adhere to prescribed medications may be associated with increased healthcare costs.
                           <span class="reference"> 
                           <a href="#referencePop293" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[293]</a> 
                           <span class="citationText" aria-hidden="true">Sorensen SV, Baker T, Fleurence R, et al. Cost and clinical consequence of antibiotic non-adherence in acute exacerbations of chronic bronchitis. Int J Tuberc Lung Dis. 2009;13:945-954.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/19723373?tool=bestpractice.com
                           </span>
                           </span>
                           Moreover, healthcare providers do not always adhere to existing guidelines for management of stable COPD or acute COPD exacerbations.
                           <span class="reference">
                              <a href="#referencePop294" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[294]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Lodewijckx C, Sermeus W, Vanhaecht K, et al. Inhospital management of COPD exacerbations: a systematic review of the literature with regard to adherence to international guidelines. J Eval Clin Pract. 2009;15
                                 <rc-c2d-number data-rc-number=":1101-1110">:1101-1110</rc-c2d-number>
                                 .
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/20367712?tool=bestpractice.com
                              </span>
                           </span>
                           This, in turn, may impact COPD exacerbation outcomes.
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Also, patients with COPD are less physically active than healthy adults and low physical activity levels are associated with a faster rate of decline in lung function and increased hospitalisations for COPD exacerbations over time.
                           <span class="reference"> 
                           <a href="#referencePop285" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[285]</a> 
                           <span class="citationText" aria-hidden="true">Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity reduces hospital admission and mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax. 2006;61:772-778.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2117100/?tool=pubmed
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/16738033?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop295" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[295]</a> 
                           <span class="citationText" aria-hidden="true">Pitta F, Troosters T, Probst VS, et al. Physical activity and hospitalization for exacerbation of COPD. Chest. 2006;129:536-544.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/16537849?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop296" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[296]</a> 
                           <span class="citationText" aria-hidden="true">Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175:458-463.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/17158282?tool=bestpractice.com
                           </span>
                           </span>
                           Pulmonary rehabilitation programmes provide exercise reconditioning and education focused on health-enhancing behaviours that can improve patients’ physical activity levels and knowledge regarding management of their disease.
                           <span class="reference"> 
                           <a href="#referencePop232" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[232]</a> 
                           <span class="citationText" aria-hidden="true">Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med. 2013;188:e13-e64.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/24127811?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop297" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[297]</a> 
                           <span class="citationText" aria-hidden="true">Cindy Ng LW, Mackney J, Jenkins S, et al. Does exercise training change physical activity in people with COPD? A systematic review and meta-analysis. Chron Respir Dis. 2012;9:17-26.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/22194629?tool=bestpractice.com
                           </span>
                           </span>
                           As such, patients’ participation in pulmonary rehabilitation programmes can play an important role in prevention of subsequent exacerbations,
                           <span class="reference"> 
                           <a href="#referencePop292" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[292]</a> 
                           <span class="citationText" aria-hidden="true">Gross N, Levin D. Primary care of the patient with chronic obstructive pulmonary disease-part 2: pharmacologic treatment across all stages of disease. Am J Med. 2008;121(suppl 7):S13-S24.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18558103?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop296" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[296]</a> 
                           <span class="citationText" aria-hidden="true">Garcia-Aymerich J, Lange P, Benet M, et al. Regular physical activity modifies smoking-related lung function decline and reduces risk of chronic obstructive pulmonary disease: a population-based cohort study. Am J Respir Crit Care Med. 2007;175:458-463.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/17158282?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop298" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[298]</a> 
                           <span class="citationText" aria-hidden="true">COPD Working Group. Pulmonary rehabilitation for patients with chronic pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-75.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384375/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23074434?tool=bestpractice.com
                           </span>
                           </span>
                           particularly when undertaken within a month following an exacerbation.
                           <span class="reference">
                              <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                              <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://journal.publications.chestnet.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1918414
                                    ">=1918414</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop238" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[238]</a> 
                           <span class="citationText" aria-hidden="true">Seymour JM, Moore L, Jolley CJ, et al. Outpatient pulmonary rehabilitation following acute exacerbations of COPD. Thorax. 2010;65:423-428.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/20435864?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Outpatient follow-up of patients within 30 days of hospital discharge following acute exacerbations also helps prevent readmissions and relapse of disease.
                           <span class="reference">
                              <a href="#referencePop289" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[289]</a> 
                              <span class="citationText" aria-hidden="true">
                                 Sharma G, Kuo YF, Freeman JL, et al. Outpatient follow-up visit and 30-day emergency department visit and readmission in patients hospitalized for chronic obstructive pulmonary disease. Arch Intern Med. 2010;170
                                 <rc-c2d-number data-rc-number=":1664-1670">:1664-1670</rc-c2d-number>
                                 .
                              </span>
                              <span class="citationFullTextUrl" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2977945/?tool=pubmed
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/20937926?tool=bestpractice.com
                              </span>
                           </span>
                           Action plans can help patients recognise worsening symptoms, initiate earlier treatment, and reduce overall impact of exacerbations.
                           <span class="reference">
                              <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                              <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://journal.publications.chestnet.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1918414
                                    ">=1918414</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                              </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop299" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[299]</a> 
                           <span class="citationText" aria-hidden="true">Howcroft M, Walters EH, Wood-Baker R, Walters JA. Action plans with brief patient education for exacerbations in chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2016 Dec 19;12:CD005074.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD005074.pub4/full
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/27990628?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#" data-trigger="click focus" data-toggle="popover" class="cochranePop" data-original-title="" title="">
                           [ <img src="/images/cca-cochrane-logo-inline.png" alt="Cochrane Clinical Answers logo"> ] 
                           </a>
                           <span class="ccaTitle" aria-hidden="true">What are the effects of action plans with limited patient education only in reducing exacerbations of chronic obstructive pulmonary disease?</span>
                           <span class="ccaUrl" aria-hidden="true">/cca.html?targetUrl=https://cochranelibrary.com/cca/doi/10.1002/cca.1545/full</span>
                           <span class="ccaHrefText" aria-hidden="true">Show me the answer</span>
                           </span>
                           Enrolment of patients in disease-management and integrated-care programmes can also be effective in reducing emergency visits and/or hospitalisations for COPD exacerbations.
                           <span class="reference"> 
                           <a href="#referencePop231" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[231]</a> 
                           <span class="citationText" aria-hidden="true">Rice KL, Dewan N, Bloomfield HE, et al. Disease management program for chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2010;182:890-896.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/20075385?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop272" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[272]</a> 
                           <span class="citationText" aria-hidden="true">Bourbeau J, Julien M, Maltais F, Rouleau M, et al. Reduction of hospital utilization in patients with chronic obstructive pulmonary disease: a disease-specific self-management intervention. Arch Intern Med. 2003;163:585-591.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://archinte.ama-assn.org/cgi/content/full/163/5/585
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/12622605?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop273" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[273]</a> 
                           <span class="citationText" aria-hidden="true">Casas A, Troosters T, Garcia-Aymerich J, et al. Integrated care prevents hospitalisations for exacerbations in COPD patients. Eur Respir J. 2006;28:123-130.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://erj.ersjournals.com/content/28/1/123.long
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/16611656?tool=bestpractice.com
                           </span>
                           </span>
                           However, their use remains somewhat controversial given that some trials have not shown any increase in time to hospital readmission,
                           <span class="reference"> 
                           <a href="#referencePop300" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[300]</a> 
                           <span class="citationText" aria-hidden="true">Bucknall CE, Miller G, Lloyd SM, et al. Glasgow supported self-management trial (GSuST) for patients with moderate to severe COPD: randomised controlled trial. BMJ. 2012;344:e1060.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3295724/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/22395923?tool=bestpractice.com
                           </span>
                           </span>
                           and one randomised controlled trial had to be stopped early due to a noted increase in mortality in the patient group randomised to comprehensive care management compared with the control group receiving guideline-based routine clinical care.
                           <span class="reference"> 
                           <a href="#referencePop88" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[88]</a> 
                           <span class="citationText" aria-hidden="true">OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser. 2012;12:1-97.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384372/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23074430?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop275" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[275]</a> 
                           <span class="citationText" aria-hidden="true">Fan VS, Gaziano M, Lew R, et al. A comprehensive care management program to prevent chronic obstructive pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med. 2012;156:673-683.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/22586006?tool=bestpractice.com
                           </span>
                           </span>
                           Self-management programmes offered immediately after acute exacerbations are associated with positive effects on patients’ knowledge, but based on existing evidence it is not possible to draw firm conclusions regarding their efficacy for other outcomes.
                           <span class="reference"> 
                           <a href="#referencePop301" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[301]</a> 
                           <span class="citationText" aria-hidden="true">Harrison SL, Janaudis-Ferreira T, Brooks D, et al. Self-management following an acute exacerbation of COPD: a systematic review. Chest. 2015;147:646-661.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/25340578?tool=bestpractice.com
                           </span>
                           </span>
                           Education with case management that includes direct access to a healthcare specialist at least monthly is recommended by evidence-based guidelines for patients with previous or recent exacerbations to reduce subsequent severe exacerbations requiring hospitalisation.
                           <span class="reference">
                              <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                              <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://journal.publications.chestnet.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1918414
                                    ">=1918414</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                              </span>
                           </span>
                           The benefits of disease management programmes likely vary depending on programme content and structure, the healthcare system in which they are implemented, and the patient population being studied. The role of hospital-at-home programmes in the management of COPD exacerbations is being studied.
                           <span class="reference"> 
                           <a href="#referencePop88" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[88]</a> 
                           <span class="citationText" aria-hidden="true">OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser. 2012;12:1-97.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384372/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23074430?tool=bestpractice.com
                           </span>
                           </span>
                           <span class="reference"> 
                           <a href="#referencePop277" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[277]</a> 
                           <span class="citationText" aria-hidden="true">McCurdy BR. Hospital-at-home programs for patients with acute exacerbations of chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-65.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384361/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23074420?tool=bestpractice.com
                           </span>
                           </span>
                        </p>
                     </li>
                     <li>
                        <p class="w-75">
                           <!-- col-md-9 -->
                           Tele-health has been used for home-based disease monitoring and management intervention.
                           <span class="reference"> 
                           <a href="#referencePop302" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[302]</a> 
                           <span class="citationText" aria-hidden="true">McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD007718.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007718.pub2/full
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/21735417?tool=bestpractice.com
                           </span>
                           </span>
                           Randomised controlled trials have suggested that the use of nurse-centred tele-assistance may decrease the occurrence of exacerbations of COPD, urgent care visits, and hospitalisation.
                           <span class="reference"> 
                           <a href="#referencePop302" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[302]</a> 
                           <span class="citationText" aria-hidden="true">McLean S, Nurmatov U, Liu JL, et al. Telehealthcare for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2011 Jul 6;(7):CD007718.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD007718.pub2/full
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/21735417?tool=bestpractice.com
                           </span>
                           </span>
                           The use of such programmes may be cost-saving.
                           <span class="reference"> 
                           <a href="#referencePop278" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[278]</a> 
                           <span class="citationText" aria-hidden="true">Vitacca M, Bianchi L, Guerra A, et al. Tele-assistance in chronic respiratory failure patients: a randomised clinical trial. Eur Respir J. 2009;33:411-418.</span> 
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/18799512?tool=bestpractice.com
                           </span>
                           </span>
                           Other analyses have suggested that home tele-monitoring may prolong the time free of hospitalisations or accident and emergency department visits,
                           <span class="reference"> 
                           <a href="#referencePop88" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[88]</a> 
                           <span class="citationText" aria-hidden="true">OHTAC COPD Collaborative. Chronic obstructive pulmonary disease (COPD) evidentiary framework. Ont Health Technol Assess Ser. 2012;12:1-97.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3384372/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23074430?tool=bestpractice.com
                           </span>
                           </span>
                           but the total number of hospitalisations may not be affected and another randomised controlled trial showed no clear beneficial effects.
                           <span class="reference"> 
                           <a href="#referencePop279" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[279]</a> 
                           <span class="citationText" aria-hidden="true">Pinnock H, Hanley J, McCloughan L, et al. Effectiveness of telemonitoring integrated into existing clinical services on hospital admission for exacerbation of chronic obstructive pulmonary disease: researcher blind, multicentre, randomised controlled trial. BMJ. 2013;347:f6070.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3805483/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/24136634?tool=bestpractice.com
                           </span>
                           </span>
                           Heterogeneity of existing studies precludes development of any firm generalisable conclusions regarding the role of tele-health in the prevention or treatment of exacerbations at the present time,
                           <span class="reference"> 
                           <a href="#referencePop303" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[303]</a> 
                           <span class="citationText" aria-hidden="true">Franek J. Home telehealth for patients with chronic obstructive pulmonary disease (COPD): an evidence-based analysis. Ont Health Technol Assess Ser. 2012;12:1-58.</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pmc/articles/pmid/23074421/
                           </span>
                           <span class="referenceUniqueId" aria-hidden="true">
                           http://www.ncbi.nlm.nih.gov/pubmed/23074421?tool=bestpractice.com
                           </span>
                           </span>
                           and as such it is not currently recommended for exacerbation prevention.
                           <span class="reference"> 
                           <a href="#referencePop1" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[1]</a> 
                           <span class="citationText" aria-hidden="true">Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. November 2017 [internet publication]</span> 
                           <span class="citationFullTextUrl" aria-hidden="true">
                           http://goldcopd.org/gold-reports/
                           </span>
                           </span>
                           <span class="reference">
                              <a href="#referencePop83" data-trigger="click focus" data-toggle="popover" class="referencePop" data-original-title="" title="">[83]</a> 
                              <span class="citationText" aria-hidden="true">Criner GJ, Bourbeau J, Diekemper RL, et al. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guideline. Chest. 2015;147:894-942.</span> 
                              <span class="citationFullTextUrl" aria-hidden="true">
                                 http://journal.publications.chestnet.org/article.aspx?articleid
                                 <rc-c2d-number data-rc-number="=1918414
                                    ">=1918414</rc-c2d-number>
                              </span>
                              <span class="referenceUniqueId" aria-hidden="true">
                              http://www.ncbi.nlm.nih.gov/pubmed/25321320?tool=bestpractice.com
                              </span>
                           </span>
                        </p>
                     </li>
                  </ul>
               </div>
         </div>
         <h2>Patient discussions</h2>
         <div class="card">
            <div class="card-block">
               <section>
                  <p class="w-75">
                        <!-- col-md-9 -->
                        <p>After an exacerbation, ensure the patient understands their usual treatment regimen and assess their inhaler technique. Discuss the importance of adhering to their routine COPD medication and explain that they may develop worsening signs and symptoms if they don&rsquo;t continue with their usual regimen as prescribed. <a href="8_AECOPD_management_prevention.html#referencePop292">[292BP]</a> A goal of managing stable COPD is to reduce further exacerbations. [1POCE]</p>
                        <p><br />In addition, advise the patient to continue with other measures that will contribute to the prevention of further exacerbations, such as seasonal vaccines, smoking cessation, and a pulmonary rehabilitation programme.</p>  
                  </p>
                  <p class="w-75">
                        <p>People with COPD tend to be less physically active than those without the condition, and low physical activity levels are associated with a faster rate of decline in lung function and increased hospitalisations for COPD exacerbations over time. <a href="8_AECOPD_management_prevention.html#referencePop285">[285BP]</a><a href="8_AECOPD_management_prevention.html#referencePop295">[295BP]</a><a href="8_AECOPD_management_prevention.html#referencePop296">[296BP]</a> Encourage patients to participate in pulmonary rehabilitation programmes, where available. Pulmonary rehabilitation is a multidisciplinary programme of care that involves physical rehabilitation as well as guidance on disease management, nutrition, and other lifestyle issues (e.g., smoking cessation, medicine compliance and inhaler technique, supplemental oxygen, and maintenance of physical activity).[35POCE] These initiatives can improve exercise tolerance, physical ability, and quality of life, therefore playing an important role in the prevention of subsequent exacerbations. [18POCE]</p>
                        <p>Consider a <strong>hospital-at-home </strong>or <strong>assisted discharge</strong> scheme, where available, <strong>once the patient is stable</strong>. [5POCE] [53POCE] [59POCE][CCA3POCE] The decision over which patients are suitable for such schemes will need a team approach, as will the implementation of such schemes. Take patient factors and preferences into account. [5POCE] Consider using a validated prognostic score, such as the DECAF score, to determine which patients are suitable for this approach. [53POCE]</p>
                        <p>Outpatient follow-up of patients within 30 days of hospital discharge following acute exacerbations also helps prevent readmissions and relapse of disease. <a href="8_AECOPD_management_prevention.html#referencePop289">[289BP]</a> Action plans can help patients recognise worsening symptoms, initiate earlier treatment, and reduce overall impact of exacerbations. <a href="8_AECOPD_management_prevention.html#referencePop83">[83BP]</a><a href="8_AECOPD_management_prevention.html#referencePop299">[299BP]</a><a href="8_AECOPD_management_prevention.html#">[ CCABP ]</a></p>
                        <p>Although tele-health is used in some regions for home-based disease monitoring and management intervention, <a href="8_AECOPD_management_prevention.html#referencePop302">[302BP]</a> it is not currently recommended for exacerbation prevention. <a href="8_AECOPD_management_prevention.html#referencePop1">[1POCE]</a><a href="8_AECOPD_management_prevention.html#referencePop83">[83BP]</a> Randomised controlled trials have suggested that the use of nurse-centred tele-assistance may decrease the occurrence of exacerbations of COPD, urgent care visits, and hospitalisation. <a href="8_AECOPD_management_prevention.html#referencePop302">[302BP]</a> The use of such programmes may be cost-saving. <a href="8_AECOPD_management_prevention.html#referencePop278">[278BP]</a> Other analyses have suggested that home tele-monitoring may prolong the time free of hospitalisations or accident and emergency department visits, <a href="8_AECOPD_management_prevention.html#referencePop88">[88BP]</a> but the total number of hospitalisations may not be affected and another randomised controlled trial showed no clear beneficial effects. <a href="8_AECOPD_management_prevention.html#referencePop279">[279BP]</a></p>

                        <p>Patients with COPD often under-report symptoms of acute exacerbation. <a href="8_AECOPD_management_patient_discussions.html#referencePop290">[290BP]</a> Regularly ask patients at clinic visits about escalation of symptoms; ensure they understand the difference between the expected day-to-day variation in symptoms and symptoms heralding a COPD exacerbation. 'Advise patients to seek clinical advice if they experience fever, worsening of their respiratory status beyond usual day-to-day variation, and/or a significant increase in their production of purulent sputum.</p>
                        <p>Advise any patient with diabetes taking systemic corticosteroids for an acute exacerbation of COPD to closely monitor their blood glucose and seek medical advice if it is outside the target range. [ref: <a href="https://www.diabetes.org.uk/resources-s3/2017-09/JBDS%20management%20of%20hyperglycaemia%20and%20steriod%20therapy_0.pdf">https://www.diabetes.org.uk/resources-s3/2017-09/JBDS%20management%20of%20hyperglycaemia%20and%20steriod%20therapy_0.pdf</a>]</p>
                        <p>In any patient prescribed antibiotics for an exacerbation:[7POCE]</p>
                        <ul>
                        <li>Give advice about possible adverse effects of the antibiotic, particularly diarrhoea.</li>
                        <li>Explain that symptoms may not be fully resolved when the antibiotic course has been completed. Give the patient/their family specific advice about when to seek further medical help; in particular if:<ul>
                        <li>Symptoms worsen rapidly or significantly</li>
                        <li>Symptoms do not start to improve within an agreed time (e.g., 2-3 days if taking antibiotics), or</li>
                        <li>The patient becomes systemically very unwell.</li>
                        </ul></li>                        
                        </ul>
                        <p>[In Follow up replace entire Monitoring section with this:]</p>
                        <ul>
                           <li><strong>Follow up patients at 1 month and 3 months (according to local service provision)</strong>. [1]<ul>
                           <li><strong>At</strong><strong>1 month</strong>: [1]<ul>
                           <li>Review discharge therapy and the patient&rsquo;s understanding of the treatment regimen</li>
                           <li>Review the need for any long-term oxygen therapy by assessing oxygen saturation and arterial blood gas</li>
                           <li>Consider any new need for antibiotics or corticosteroids</li>
                           <li>Reassess inhaler technique</li>
                           <li>Evaluate the patient&rsquo;s ability to cope in their usual environment.</li>
                           <li>Document their physical capabilities</li>
                           <li>Document current symptoms</li>
                           <li>Assess and manage comorbidities.</li>
                           </ul></li>                        
                           </ul></li>
                           <li><strong>At 3 months ensure the patient has returned to a stable clinical state</strong>: [1]
                              <ul>
                              <li>Review symptoms</li>
                              <li>Review the patient&rsquo;s understanding of the treatment regimen</li>
                              <li>Reassess inhaler technique</li>
                              <li>Document their physical capabilities</li>
                              <li>Check lung function by spirometry</li>
                              <li>Check oxygen saturations and blood gas to assess the need for ongoing long-term oxygen therapy</li>
                              <li>Assess prognosis using a scoring system, such as BODE</li>
                              <li>Assess and manage comorbidities</li>
                              <li>Request a CT to check for the presence of bronchiectasis or emphysema in patients with recurrent exacerbations.</li>
                              </ul>
                           </li>
                           <li><strong>Advise the patient to continue with other measures that will contribute to the prevention of further exacerbations, such as seasonal vaccines, smoking cessation, and a pulmonary rehabilitation programme. </strong></li>
                           <li>Some presentations of an exacerbation actually represent ongoing deterioration and disease progression.</li>
                        </ul>
                        
               </section>
            </div>
         </div>


         <div class="row">
            <div class="card-block disclaimer">
               <p><span>Use of this content is subject to our <a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">disclaimer</a> </span></p>
            </div>
         </div>
      </main>
      <script type="text/javascript" id="">(function(){var f=google_tag_manager["GTM-K3TZ3JV"].macro(4),b=google_tag_manager["GTM-K3TZ3JV"].macro(5),a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};f?"true"!=b&&("justLoggedIn"==b?a("loggedIn","true",2):a("loggedIn","justLoggedIn",2)):a("loggedIn","false",2)})();</script><script type="text/javascript" id="">var meta=document.createElement("meta");meta.name="msvalidate.01";meta.content="76FD53F39FDFB050A93D7925608BA016";document.getElementsByTagName("head")[0].appendChild(meta);</script>
      <!-- set the messages country code variable from region to be used from i18 plugin. Setting here so it's available in all pages -->
      <script>
         /*<![CDATA[*/
         
         var messagesCountryCode = "en_GB";
         /*]]>*/
           
      </script>
      <aside id="panel-nhs" class="card-block">
         <div id="access" class="col-sm-6">
            <div class="row">
               <div class="col-md-6">
                  <p>Access provided by:</p>
               </div>
               <div class="col-md-6">
                  <img src="../images/bmj-logo.png" alt="BMJ Group (Online access from BMA House)">
               </div>
            </div>
         </div>
      </aside>
      <footer id="footer">
         <div class="container">
            <div class="row">
               <nav class="col-md-9" role="navigation">
                  <div class="row">
                     <dl class="col-md-4" role="menu">
                        <dt>Browse</dt>
                        <dd><a href="https://bestpractice.bmj.com/">Home</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/recent-updates">Recent updates</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/specialties">Specialties</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/calculators">Calculators</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/patient-leaflets">Patient leaflets</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/procedural-videos">Procedural videos</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/evidence">Evidence</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/drugs">Drugs</a></dd>
                     </dl>
                     <!-- logged-in individual or institutional user -->
                     <dl class="col-md-4" role="menu">
                        <dt>Services</dt>
                        <dd id="footerLogout">
                           <form method="POST" action="https://bestpractice.bmj.com/logout" role="menuitem">
                              <input type="hidden" name="loggedIn" id="loggedIn" value="true">
                              <button type="submit" value="Log out">Log out</button>
                           </form>
                        </dd>
                        <dd>                        
                           <a href="https://myaccount.bmj.com/myaccount/account/home-view.html?fwdUrl=https://bestpractice.bmj.com" target="_blank">
                           My details
                           </a>  
                        </dd>
                        <dd hidden="hidden">           
                           <a href="https://myaccount.bmj.com/myaccount/account/home-view.html#email-matrix-container?fwdUrl=https://bestpractice.bmj.com" target="_blank">
                           My emails
                           </a>  
                        </dd>
                        <dd><a href="https://bestpractice.bmj.com/activity">CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/getting-started/">Getting started</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/faq/">FAQs</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/earn-cme-points/">About CME/CPD</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/benefits-features/">About us</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/app/">Mobile app</a></dd>
                        <dd><a href="https://bestpractice.bmj.com/info/contact-us/">Contact us</a></dd>
                        <dd>
                           <a href="https://myaccount.bmj.com/myaccount/registration.html?regService=bestpractice-email-alert&amp;fwdUrl=https://bestpractice.bmj.com">
                           Sign up for email alerts
                           </a>
                        </dd>
                     </dl>
                     <!-- unknown user -->
                     <!--institutional user not logged in-->
                     <dl class="col-md-4" role="menu">
                        <dt>Legal</dt>
                        <dd><a href="https://bestpractice.bmj.com/info/disclaimer/" target="_blank">Disclaimer</a></dd>
                        <dd><a href="https://www.bmj.com/company/legal-information/" target="_blank">Terms and conditions</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/" target="_blank">Privacy notice</a></dd>
                        <dd><a href="https://www.bmj.com/company/your-privacy/cookies-policy/" target="_blank">Cookie policy</a></dd>
                     </dl>
                  </div>
                  <!-- row -->
               </nav>
               <div class="col-md-3">
                  <ul>
                     <li><a target="_blank" href="https://www.facebook.com/BMJBestPractice"><img alt="Facebook Logo" title="Facebook" src="../images/facebook-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://twitter.com/BMJBestPractice"><img alt="Twiter Logo" title="Twitter" src="../images/twitter-64.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.linkedin.com/showcase/15218227/"><img alt="LinkedIn Logo" title="LinkedIn" src="../images/linkedIn_logo_circle.png" width="60" height="60"></a></li>
                     <li><a target="_blank" href="https://www.youtube.com/channel/UCt72GZ0cPXpk4EzgFhdWYdQ"><img alt="Youtube Logo" title="YouTube" src="../images/youtube-64.png" width="60" height="60"></a></li>
                  </ul>
                  <p class="copyright mt-3"><small>© BMJ Publishing Group 2018</small></p>
                  <p class="issn">
                     <small>
                        ISSN
                        <rc-c2d-number data-rc-number=" 2515-9615"> 2515-9615</rc-c2d-number>
                     </small>
                  </p>
               </div>
            </div>
            <!-- row -->  
         </div>
         <!-- container -->    
      </footer>
      <div class="container modal-registration-form" aria-hidden="true">
         <div id="feedbackContainer" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-header">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Help us improve <abbr>BMJ</abbr> Best Practice</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                        <div class="col-md-12">
                           <p>Please complete all fields.</p>
                        </div>
                     </div>
                  </div>
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <form id="feedbackForm" action="https://bestpractice.bmj.com/topics/en-gb/8#" novalidate="novalidate">
                              <div class="row">
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackName">Name</label> 
                                       <input id="feedbackName" class="form-control" name="feedbackName" type="text">
                                    </div>
                                 </div>
                                 <div class="col-md-6">
                                    <div class="form-group floating-label">
                                       <label for="feedbackEmail">Email</label> 
                                       <input id="feedbackEmail" class="form-control" name="feedbackEmail" type="email" value="stailor@bmj.com">
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <h2 id="feedbackPageTitle" class="h3">Page: Acute exacerbation of chronic obstructive pulmonary disease - Symptoms, diagnosis and treatment | BMJ Best Practice</h2>
                                 </div>
                              </div>
                              <input id="feedbackPage" name="feedbackPage" type="hidden" value="Acute exacerbation of chronic obstructive pulmonary disease - Symptoms, diagnosis and treatment | BMJ Best Practice">
                              <div class="row">
                                 <div class="col-md-4">
                                    <p>I have some feedback on:</p>
                                    <fieldset class="form-group" role="radiogroup">
                                       <legend>Feedback on: </legend>
                                       <label for="feedOn01"><input id="feedOn01" type="radio" name="feedbackOn" value="This page" checked="checked">&nbsp;This page</label>
                                       <label for="feedOn02"><input id="feedOn02" type="radio" name="feedbackOn" value="This website">&nbsp;The website in general</label>
                                       <label for="feedOn03"><input id="feedOn03" type="radio" name="feedbackOn" value="Something else">&nbsp;Something else</label>
                                    </fieldset>
                                 </div>
                                 <div class="col-md-8">
                                    <div class="form-group floating-label textarea">
                                       <label for="feedbackContent">I have some feedback on:</label>
                                       <textarea id="feedbackContent" name="feedbackContent"></textarea>
                                    </div>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <p>We will respond to all feedback.</p>
                                 </div>
                              </div>
                              <div class="row">
                                 <div class="col-md-12">
                                    <button id="feedbackSubmit" type="submit" class="btn btn-secondary btn-lg">
                                    <span id="spinner2" class="progress-circular-inner progress-circular-left"></span>
                                    <span id="btnText2">Submit Feedback</span>
                                    </button>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-12">
                                    <p>For any urgent enquiries please contact our customer services team who are ready to help with any problems.</p>
                                 </div>
                              </div>
                              <div class="row smTxt">
                                 <div class="col-md-3">
                                    <p>
                                       <b>Phone:</b> 
                                       <rc-c2d-number data-rc-number="+44 (0) 207 111 1105">+44 (0) 207 111 1105</rc-c2d-number>
                                    </p>
                                 </div>
                                 <div class="col-md-3">
                                    <p><b>Email: </b> <a href="mailto:support@bmj.com">support@bmj.com</a></p>
                                 </div>
                              </div>
                           </form>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedbackSuccess" class="modal fade" tabindex="-1" role="dialog" aria-labelledby="ModalFeedbackConfirmedLabel" aria-hidden="true">
            <div class="modal-dialog modal-lg" role="document">
               <div class="modal-content pb-3">
                  <div class="modal-body">
                     <div class="row">
                        <div class="col-md-12">
                           <h2>Thank you</h2>
                           <button type="button" class="close" data-dismiss="modal" aria-label="Close">
                           <span aria-hidden="true">×</span>
                           </button>
                        </div>
                     </div>
                     <div class="row">
                        <div class="col-md-12">
                           <p>Your feedback has been submitted successfully.</p>
                        </div>
                     </div>
                  </div>
               </div>
            </div>
         </div>
         <div id="feedBackBtn">
            <p role="button"><a href="https://bestpractice.bmj.com/topics/en-gb/8#"><span class="material-icons"></span>&nbsp;FEEDBACK</a></p>
         </div>
      </div>
      <script type="text/javascript" src="../js/common.js"></script>
      <script type="text/javascript" src="../js/main.js"></script>
      <script>
         // Code for the recently viewed topics suggestion, needs to be inlined to use the Java values
         /*<![CDATA[*/       
         function dedupe(array) {
           var seen = {};
           return array.filter(function(item) {
               return seen.hasOwnProperty(item.id) ? false : (seen[item.id] = true);
           });
         }
         function TopicViewed(id, title, lang) {
           this.id = id;
           this.title = title;
           this.lang = lang;
         }
         jQuery(document).ready(function() {
           var topicId = 8;
           var topicLang = "en-gb";
           var topicTitle = "Acute exacerbation of chronic obstructive pulmonary disease";
           if(topicId){
               
             var topicsViewed = [];
             if (localStorage.getItem("topicsViewed") !== null) {
               topicsViewed = JSON.parse(localStorage.topicsViewed);
             }
               
             topicsViewed.unshift(new TopicViewed(topicId, topicTitle, topicLang));// Add new topics at the beginning
             topicsViewed = dedupe(topicsViewed);// Remove duplicates
             if (topicsViewed.length > 15){// Drop if size is bigger than 15
               topicsViewed = topicsViewed.slice(0,14);  
             }
         
             localStorage.topicsViewed = JSON.stringify(topicsViewed);
           }
          });       
         /*]]>*/
      </script>
      <script type="text/javascript">
         _linkedin_data_partner_id = "103646";
      </script>
      <script type="text/javascript">
         (function()
         {var s = document.getElementsByTagName("script")[0]; var b = document.createElement("script"); b.type = "text/javascript";b.async = true; b.src = "https://snap.licdn.com/li.lms-analytics/insight.min.js"; s.parentNode.insertBefore(b, s);}
         )();
      </script>
      <script type="text/javascript" data-cfasync="false">
         (function(W,i,s,e,P,o,p){W['WisePopsObject']=P;W[P]=W[P]||function()
         { (W[P].q=W[P].q||[]).push(arguments)}
         ,W[P].l=1*new Date();o=i.createElement(s),
         p=i.getElementsByTagName(s)[0];o.async=1;o.src=e;p.parentNode.insertBefore(o,p)
         })(window,document,'script','//loader.wisepops.com/get-loader.js?v=1&site=qudyiEfMBd','wisepops');
         window.WisePopsLoaderCallback = function(wisepops) {
                         wisepops._storage.visits = wisepops._storage.visits.slice(0, 2);
                         wisepops._storage._saveVisits();
                       };
      </script>
      <noscript>
         <img height="1" width="1" style="display:none;" alt="" src="https://dc.ads.linkedin.com/collect/?pid=103646&fmt=gif" />
      </noscript>
      <!--[if lte IE 7]><script>var isIE7OrOlder = true; </script><![endif]-->   
      <!--[if lte IE 9]><script type="text/javascript" src="/gzip_e7393341757851d76c3264b590cf5143/js/browserupdate.js" ></script>
      <![endif]-->
      <script type="text/javascript" id="createCookie">(function(){var b="bestpractice.bmj.com\/topics\/en-gb\/8",a=function(a,b,d){var e="",c=new Date;d&&(c.setTime(c.getTime()+864E5*d),e="; expires\x3d"+c.toGMTString());document.cookie=a+"\x3d"+b+e+"; path\x3d/; domain\x3dbmj.com"};a("RefTrack",b,2);a("RefTrackGroup","bestpractice.bmj.com",2)})();</script><script type="text/javascript" id="copyText">function getSelectionText(){var a="";window.getSelection?a=window.getSelection().toString():document.selection&&"Control"!=document.selection.type&&(a=document.selection.createRange().text);return a}document.addEventListener("copy",function(a){dataLayer.push({event:"textCopied",clipboardText:getSelectionText(),clipboardLength:getSelectionText().length})});</script>
      <script type="text/javascript" id="facebookPixel">!function(b,e,f,g,a,c,d){b.fbq||(a=b.fbq=function(){a.callMethod?a.callMethod.apply(a,arguments):a.queue.push(arguments)},b._fbq||(b._fbq=a),a.push=a,a.loaded=!0,a.version="2.0",a.queue=[],c=e.createElement(f),c.async=!0,c.src=g,d=e.getElementsByTagName(f)[0],d.parentNode.insertBefore(c,d))}(window,document,"script","https://connect.facebook.net/en_US/fbevents.js");fbq("init","414393182248444");fbq("track","PageView");</script>
      <noscript><img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=414393182248444&amp;ev=PageView&amp;noscript=1"></noscript>
      <rc-c2d-menu class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenu--2ChJF">
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dMenuWrapper--2XS05">
            <img class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__c2dLogo--3d0gU" src="data:image/png;base64,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">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__callBtn--g4JAI _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="Call with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 24 26">
                  <path fill="#0083BF" fill-rule="evenodd" stroke="#0684BD" stroke-width=".9" d="M6.656 17.651C.942 10.547.28 4.627 2.545 2.607c.592-.522 2.16-1.323 2.892-1.427.801-.14 1.602.243 2.02 1.01.802 1.636 1.777 3.238 2.788 4.805.452.697.348 1.567-.244 2.16-.349.348-.767.557-1.15.765a3.18 3.18 0 0 0-.801.523s-.105.104-.105.313c-.035.453.035 1.707 2.02 4.214 2.16 2.647 3.45 2.82 3.798 2.82.14 0 .244-.034.244-.034.244-.21.453-.453.662-.697.314-.348.593-.696 1.01-.975.697-.452 1.638-.348 2.16.21 1.325 1.323 2.753 2.576 4.112 3.76.662.557.906 1.428.557 2.16-.244.66-1.359 2.02-2.02 2.541-.558.488-1.324.697-2.195.697-3.345 0-7.7-2.925-11.637-7.8z"></path>
               </svg>
            </div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__separatorLine--wHeg7 _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v"></div>
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__smsBtn--b7MAc _6772342E312E39_src-lib-ExtensionContentRunner-styles__visible--1Jw-v" title="SMS with RingCentral">
               <svg xmlns="http://www.w3.org/2000/svg" width="18" height="18" viewBox="0 0 22 21">
                  <path fill="#0684BD" fill-rule="nonzero" d="M10.944.014C4.91.014.007 4.068.007 9.316c0 2.86 1.54 5.626 4.085 7.417-.094.534-.377 1.257-1.162 2.64l-.692 1.131h1.383a6.976 6.976 0 0 0 4.84-1.917c.817.157 1.634.252 2.483.252 6.034 0 10.936-4.275 10.936-9.523 0-5.28-4.902-9.302-10.936-9.302z"></path>
               </svg>
            </div>
         </div>
         <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__arrow--1GYRr">
            <div class="_6772342E312E39_src-lib-ExtensionContentRunner-styles__innerArrow--2JsQO"></div>
         </div>
      </rc-c2d-menu>
      <script src="../js/adsct.js" type="text/javascript"></script><script src="../js/saved_resource.js" type="text/javascript"></script>
   </body>
</html>